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INTRODUCTION 
  “Pain, like pleasure is passion of the soul, 
    That is an emotion and not one of the senses”  
                                                   -    PLATO and ARISTOTLE (375 B.C) 
  Pain is a fundamental biological phenomenon.The International 
Association for the Study of Pain has defined pain as “an unpleasant 
sensory and emotional experience associated with actual or potential 
tissue damage, or described in terms of such damage.” Pain is always 
underestimated and undertreated. The relief of pain during surgery is 
the main part of anaesthesia. 
 In 1784 James Moore used mechanistic concepts to promote 
neural compression as a useful technique for the provision of surgical 
anaesthesia. 
 In 1855, neurologic pain can be treated by circum-neural injection 
of pain relieving drug. At the same year Gadecke (German) isolated 
alkaloid from leaves of coca plant. In 1860 Albert Nieemann was 
successful in isolating and naming the alkaloid from the leaves of 
erythroxylon coca. 
  In 1911, Kullenkampff introduced the classic supraclavicular 
approach of brachial plexus block. Winnie and Collins introduced the   
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subclavian perivascular approach of brachial plexus block. After 
introduction of barbiturate and cyclopropane, the enthusiasm for block 
anaesthesia waned in early 1940s.  
In current recent years however, the technique has had resurgence, 
due in large part to increased understanding of neural plasticity and the 
possibility of minimizing hospital stay by effective use of regional block. 
Several experimental and clinical studies have shown that alpha-2 
adrenergic agonists like clonidine were able to prolong sensory and 
motor blockade. The conventional parasthesia technique being a blind 
technique may be associated with higher failure rate, injury to nerves & 
vascular structures. To minimize these drawbacks, various techniques 
and approaches were described. Among them, ultrasound visualization 
of anatomical structure is  the only method offering safe blocks of 
superior quality by optimal needle positioning. Ultrasound has improved 
success rate with excellent localization & improved safety margin.. 
This study was aimed to evaluate the clinical efficacy of clonidine 
as an adjuvant to 0.75% ropivacaine for enhancing the quality and 
duration of motor and sensory block along with duration of analgesia of 
ultrasound guided supraclavicular brachial plexus block in upper limb 
surgeries. 
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AIM OF THE STUDY 
To evaluate the effectiveness of CLONIDINE AS AN 
ADJUVANT FOR ULTRASOUND GUIDED SUPRACLAVICULAR 
BRACHIAL PLEXUS BLOCK FOR UPPER EXTREMITY 
SURGERIES UNDER TOURNIQUET for prolonging the 
1. Onset of sensory blockade 
2. Onset of motor blockade 
3. Duration of sensory blockade 
4. Duration of motor blockade 
5. Duration of analgesia 
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ANATOMICAL CONSIDERTIONS 
Knowledge of the formation of brachial plexus and of its 
distribution is absolutely essential to the intelligent and effective use of 
brachial plexus anaesthesia for surgeries of the upper limb. Close 
familiarity with the vascular, muscular and fascial relationships of the 
plexus throughout its formation and distribution is equally essential to 
the mastery of the various techniques of brachial plexus blockade. 
FORMATION OF PLEXUS 21 
Roots 
      The plexus is formed by the anterior primary rami of the 5th to 8th 
cervical nerves, together with the bulk of the 1st thoracic nerve (C -8 and 
T1). In addition there is frequently a contribution above from C4 to the 
5th cervical root and another below from T2 to the 1st thoracic nerve. 
Occasionally the plexus is mainly derived from C4 - 8 (Pre -fixed 
plexus) or from C6 - T2 (post - fixed plexus). 
Trunks 
The five roots of the plexus emerge from the intervertebral 
foramina. They lie in the gutter between the anterior and posterior 
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tubercles of the corresponding transverse process. All five roots then 
become sandwiched between scalenus anterior and medius.  
Here the roots of C5 and C6 unite into the upper trunk. The 
root of C7 continues as the middle trunk and those of C8 and T1 into 
the lower trunk. Each trunk divides behind the clavicle, into anterior and 
posterior divisions, which unite in the axilla to form the cords. 
Cords 
The six divisions stream into the axilla and there unite up into 
three cords. Lateral, medial and posterior. These cords are composed as 
follows: 
The union of the anterior divisions of the upper and middle trunks 
forms the lateral cord. The medial cord represents the continuation of 
the anterior division of the lower trunks. The posterior cord comprises 
of all three posterior divisions. 
The composition of the brachial plexus can be summarized as follows: 
1.  Five roots - the anterior primary rami of C5 - 8 and T1 
2.  Three trunks. 
      a)  Upper trunk, C5 and C6 
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      b) Middle trunk, C7 alone and  
      c)  Lower trunk, C8 and T1 
3.  Six divisions - each trunk divides into an anterior and posterior 
division. 
4.  Three  cords 
          a)  Lateral cord, the fused anterior divisions of upper and middle 
trunks (C5 - C7) 
       b)  Medial cord, the anterior division of the lower trunk (C8, T1) 
           c) Posterior cord, formed by the union of the posterior division 
of all three  trunks (C5, T1). 
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RELATIONS OF THE BRACHIAL PLEXUS 
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Roots 
Lie between the scalenus anterior and medius. The roots of the 
plexus lie above the second part of the subclavian artery. 
Trunks 
The upper and middle trunks lie above the subclavian artery as the 
stream across the 1st rib, but the lower trunk lies behind the artery and 
may groove the rib immediately posterior to the subclavian groove. 
Division 
At the lateral border of the 1st rib the trunks bifurcate into 
divisions, which are situated behind the clavicle. 
Cords 
The cords are formed at the apex of the axilla and become 
grouped around the axillary artery. 
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BRANCHES OF BRACHIAL PLEXUS 
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BRANCHES 
Branches are given off from 
1.   Roots 
2.   Trunks and 
3.   Cords 
3.1 Branches from the Roots 
3.1.1. Nerve to the serratus anterior          (C5, C6 and C7) 
3.1.2. Muscular branches to 
i. Longus cervices      (C5- C8) 
 ii. Three scalene     (C5 - C8)  
iii. Rhomboids      (C5) 
3.1.3. A twig of Phrenic nerve    (C5) 
3.2 Branches from the trunks 
3.2.1. Suprascapular nerve    (C5,C6) 
3.2.2. Nerve to subclavius     (C5,C6) 
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BRANCHES FROM THE CORDS  
LATERAL CORD 
i.    Lateral pectoral nerve    (C5 - C7) 
ii.   Lateral head of median nerve  (C5 - C7)  
iii.  Musculocutaneous nerve   (C5 - C7)  
MEDIAL CORD 
i.    Medial pectoral nerve    (C8 - T1) 
ii.   Medial head of median nerve  (C8 - T1) 
iii.   Medial cutaneous nerve of arm  (C8 - T1) 
 iv.  Medial cutaneous nerve of forearm (C8 -T1) 
 v.   Ulnar nerve      (C8- T1)  
POSTERIOR CORD 
i.    Upper subscapular nerve                        (C5 - C6) 
ii.   Lower subscapular nerve                       (C5 - C6) 
 iii.  Nerve to latissimus dorsi                       (C5 - C6)  
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iv.  Axillary nerve                                     (C5 - C6) 
 v.  Radial nerve                                        (C5 - C6)  
TECHNIQUE OF BRACHIAL PLEXUS BLOCK 
Surgical anaesthesia of the upper extremity and shoulder can be 
obtained following neural blockade of the brachial plexus at several 
sites. The various approaches that can be used for this blockade are as 
follows. 
1.Interscalene approach 
2. Supraclavicular approach 
  a. Classic approach 
b. Plumb -bob technique 
c. Subclavian perivascular technique 
3. Axillary approach 
4. Infraclavicular approach 
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BASICS OF ULTRASOUND 
The frequency of medical ultrasound ranges between 2 MHz and 
13 MHz. The average wave length in this band is about 1 mm. This 
limits the resolution to structures that are  larger than 1 mm. Most nerves 
of interest range in size from 2 mm to 10 mm. Veins and arteries of 
interest are typically 3 mm to 15 mm. 
Many factors contribute to the quality and resolution of the 
ultrasound image. In general, higher frequency probes generate higher 
resolution images.  
Unfortunately, high frequency ultrasound waves (8 MHz to 13 MHz) 
are rapidly attenuated in tissues so that high frequency probes are best 
suited for structures less than 5 cm deep to the skin. 
The image formed of a nerve on ultrasound is very sensitive to the 
angle of incidence of the beam relative to the nerve. Sometimes changing 
the angle of incidence by only a few degrees can bring the nerve into focus. 
This phenomenon is thought to be caused by diffraction of the type 
described above.  
Modern platforms allow the user to adjust the brightness (gain) of the 
entire image or more superficial (near field) and deep (far field) structures. 
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IMAGE OF VESSELS: 
Arteries can usually be distinguished by their pulsatile nature. 
Veins can be distinguished by their compressibility. Color flow Doppler 
imaging can also be used to identify and  distinguish arteries and veins. 
By convention, blood flowing toward the probe is colored red. Blood 
flowing away from the probe is colored blue. Blood flowing 
perpendicular to the probe remains black. Velocity gates can be set to 
measure the flow velocity. High velocities are usually arteries. Low 
velocities are usually veins. Transducer elements can be arranged in 
linear or curved arrays. 
 
PROBE SELECTION: 
Linear arrays create rectangular images and are most useful for 
superficial structures. Curved arrays create wedge-shaped images and are 
most useful for deeper structures. Because the beam disperses in a 
curved array, its resolution is usually lower than a  linear array. A phased 
array retains the elements in a straight line. But the elements fire in 
sequence creating a phase delay between each element. The net result is 
a wedge-shaped image from a set of linear transducers. Because this 
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signal is averaged, its resolution is also lower than a standard linear 
array.  
Most probes have transducers that emit the highest amplitude of 
their  ultrasound wave at a specific fundamental frequency. Harmonics 
of this frequency are also emitted at lower amplitudes. By listening for 
the echo at these higher harmonic frequencies, image resolution can be 
enhanced. Because the harmonics are very low amplitude, only 
transducers that have sufficient power  output can be used for harmonic 
imaging. This type of image enhancement is referred to as tissue 
harmonic imaging. 
Modern probes operate in pulsed mode. The transducer elements 
in the probe are used as both transmitters and receivers. The transducer 
elements emit a short ultrasound burst and then wait for the echo before 
emitting another ultrasound burst. This allows the probe to be smaller 
compared with continuous wave probes where there are separate emitters 
and transducers. 
When a needle is inserted into tissue perpendicular to the 
ultrasound beam, it is a good   reflector and it is easy to image. In some 
cases, it may be necessary to insert the needle nearly parallel to the beam 
in order to reach the targeted organ The collar bone, nerves are usually 
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dark (hypoechoic). Nerves located below the collar bone are usually 
white (hyperechoic). The reasons for this dichotomy are not known, but 
it may be related to the depth of the nerves and the relative amounts of 
fat and stroma within the nerves themselves. On ultrasound cross 
section, nerves are round, hypo or hyperechoic, reticulated structures. 
When imaged along their long axis, nerves appear as linear, hypo or 
hyperechoic streaks, on ultrasound. Bones are hyperechoic and  usually 
very bright white. Arteries and veins are black unless color flow Doppler 
imaging is used. 
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PHYSIOLOGICAL CONSIDERATION 2,3 
Pain perception requires noxious stimuli. It is transformed from 
its native form by the activated nociceptors into electrical signals 
which are then transmitted along the corresponding nociceptive fibres. 
These fibres in turn synapse onto second order neurons in the spinal 
cord. These interneurons are  located  in  the dorsal  horn.  It  is  at 
these interneurons  where the  initial modulation of nociceptive input 
occurs. From the spinal cord nociceptive input is transmitted to the 
brain stem, thalamus and cortex. 
Peripheral neuroanatomy of nociception 
C and A fibres are the main peripheral nociceptors. The skin 
joints and periosteum are richly innervated with C and A  nociceptors 
as well as the non nociecptive Aβ sensory fibres. 
A   are responsible for the sensation  of first  pain, the initial  
sharp  pain experienced following an injury. C fibres are unmyelinated 
and are responsible for second pain, the slowly building throbbing 
burning pain experienced following an injury. 
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Classification of sensory fibres 
 
 
 
 
Sensory 
receptors 
Speed of 
Transmission Sensory function Myelination 
A-Alpha fibres  70 -120m/sec 
Noxious chemical thermal, 
mechanical stimuli, (sharp fast, 
first pain) 
Lightly 
myelinated 
A-Beta fibres  30 -70m/sec 
Nonpainful, light touch, 
pressure, vibration 
proprioception 
Heavily 
myelinated 
A-Gamma fibres  30-70m/sec Proprioception/Motor to 
muscle spindle Myelinated 
A-Delta fibres  12 -30 m/sec Pain, cold, touch Myelinated 
B fibres  3 -15 m/sec 
Pre ganglionic 
autonomic 
(sympathetic) 
Myelinated 
C Fibres  0.5 -2m/sec 
Noxious chemical, 
 
Mechanical, thermal activation 
(Slow burning second pain) 
Unmyelinated 
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Peripheral neurochemistry and neurotransmitters : 
Commonly released inflammatory mediators implicated in pain 
and hyperalgesia include bradykinins, potassium, substance P 
cytokines, histamine, serotonin, prostaglandins. These peripheral 
neurotransmitters either activate or sensitise the peripheral nociceptors 
to pain. 
Peripheral neuro chemistry Algogenic Agents : 
    Algogenic Agent Action on nociceptors 
Bradykinin Activates 
Substance P Sensitizes 
                       Potassium Activates 
                       Hydrogen Activates 
    Arachidonic acid Sensitizes 
                       Cytokiness Sensitizes 
                       Serotonin Sensitizes 
                       Noradrenaline 
 
 High concentration activates 
and sensitizes after injury. 
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PHERIPHERAL ALPHA 2 RECEPTORS 
Alpha 2 adrenoreceptors are located on primary afferent terminal. 
Clonidine enhances both sensory and motor blockade from peripheral 
nerve injection and epidural / spinal injection of local anaesthetics. 
Clonidine  blocks  conduction  of C  and  A  gamma  fibers  and  
increase potassium conductance in isolated neurons and intensifies 
conduction block of local anaesthetics. 
 Local vasoconstriction resulting in reduced absorption from 
injection site was another point of discussion, but compared with 
adrenaline as adjuvant it failed to influence plasma levels, indicating a 
direct action on nerve. 
PAIN PATHWAY 
 SPINAL CORD 
The gray matter of the spinal cord is divided into ten lamina 
with lamina I – IV representing the dorsal horn. The dorsal horn is 
capped by the Lissauer’s tract which consists of branches of cutaneous 
A and C – fibres and few visceral afferents. 
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Nociceptive fibres terminate in the superficial layers of lamina 
I & II while the non-painful myelinated fibres terminate in the deeper 
layers of lamina III,IV. Lamina II has the highest concentration of 
opioid receptors in the spinal cord. Modulation and inhibition of 
nociception may occur at this level through the use of opioids (systemic 
and neuraxial). 
Ascending sensory pathways 
Peripheral sensory neurons synapse onto the secondary 
interneurons of the dorsal horn. The axons of the non nociceptive 
secondary neurons travel isobilateral in the dorsal columns of the 
spinal cord as fasciculus cuneatus (upper body through T6) and 
fasciculus gracilis (lower body below T6) and synapse in thalamus. 
The axons of the nociceptive secondary neurons after synapsing, 
travel contra laterally in the anterolateral aspects of the spinal cord as 
the neospinothalamic and paleospinothalamic tract. 
Neospinothalamic tract carries fine discrimination of pain eg. 
Location, intensity, and first pain. 
Paleospinothalamic tract responds to noxious stimuli. The paleo 
spinothalamic tract synapses in the thalamus, hypothalamus and limbic 
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system and plays a role in emotional aspects of pain via limbic 
system. The thalamus has multiple connections to limbic system and 
cortex. 
Descending inhibitory pathways 
The descending controls of pain project specifically onto laminas 
I, II, V of the dorsal horn from mesencephalon, raphenuclei and 
reticular tract. The mesencephalon is rich in opioid receptors. This area 
sends excitatory transmissions to the rostroventral medulla which sends 
noradrenaline and serotonin inhibitory tracts via the dorsolateral  
funiculus  to lamina I,II,V of spinal cord. 
The noradrenaline and serotonin fibres mediate transmission 
between the primary  afferents  and  the  secondary  neurons  of  the  
dorsal  horn. Increased activity of these fibres leads to increased 
inhibition of pain transmission. 
Location of Alpha2 receptors  
Primary afferent terminals, on neurons in the superficial laminae 
of spinal cord and brainstem nuclei. 
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Location of opioid receptors (central) 
Opioid  receptors  are  found  in  the  various  regions  in  CNS  
namely, cerebral cortex, limbic cortex (anterior and posterior amygdale, 
hippocampus hypothalamus, medial thalamus, mid brain, periaqueductal 
gray matter, extrapyramidal areas, substantia gelatinosa and sympathetic 
preganglionic neurons. 
Opioid receptors are also found in the cardiac sympathetic fibres, 
cardiac branches of vagus, adrenal medulla, and gastro intestinal tract. 
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PHARMACOLOGY OF ROPIVACAINE 
 
        Ropivacaine is a new aminoamide local anaesthetic. It is the 
monohydrate of the hydrochloride salt of 1-propyl - 2, pipecoloxylidide 
and is prepared as a pure S - enantiomer. 
Pipecoloxylidides were first synthesized in 1957 and have been in 
clinical use of more than 30 years. Ropivacaine has a propyl group on 
the piperidine nitrogen atom of the molecule. 
The Pipecoloxylidides are chiral drugs because the molecules 
possess an asymmetric carbon atom and they may have left - (sinister) 
or right (rectus) handed configuration. 
 
.ROPIVACAINE HYDROCHLORIDE 
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PHYSIO-CHEMICAL PROPERTIES 
 
The physio-chemical properties of Ropivacaine are as follows : 
 
1.  Molecular weight (base)                                -  274 
 
2.  pKa                                                                 -  8.1 
 
3.  Partition coefficient (N Heptane / buffer)      -  2.9 
 
4.  Mean uptake ratio (rat sciatic nerve)             -  1.8 
 
5.  Protein binding                                               - 94% 
 
PHARMACOLOGIC PROPERTIES 
 
Onset                       -        Moderate 
 
Relative potency     -        6 
 
Duration                 -        Long acting 
 
Mechanism of action 
 
Ropivacaine blocks the generation and conduction of nerve 
impulses, presumably by increasing the threshold for electrical 
excitation in the nerve, by slowing the propagation of the nerve 
impulses, and by reducing the rate of rise of action potential. The 
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progression of anaesthesia is related to the diameter, myelination and 
conduction velocity of affected nerve fibers.  
     The order of loss of nerve function clinically is as follows : 
1.  Pain 
2.  Temperature 
3.  Touch 
4.  Proprioception 
5.  Skeletal muscle tone 
 
Pharmacokinetics 
In human volunteers the pharmacokinetic characteristics of 
ropivacaine have been determined after intravenous infusion 
Clearance                                                      : 0.82  ± 0.16 litres /min 
Plasma protein binding                                 : 94 ± 1% 
Volume of distribution at steady state          : 59 ± 7 liters (Vss) 
Terminal elimination ½ life                          :111 ± 62min 
Metabolism: Liver by aromatic hydroxylation by cytochrome 
P450 1A to 3-hydroxyl ropivacaine. 
Excretion: 86% via the kidney 1% unchanged drug, rest as 
metabolites the higher clearance of ropivacaine over bupivacaine is 
advantageous in terms of lesser systemic toxicity. 
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Absorption 
The systemic concentration of ropivacaine is dependent on the 
total dose and concentration  of  drug  administered,  the  route  of  
administration, the patient’s haemodynamic condition and the 
vascularity of the administration site. From the epidural space, 
ropivacaine shows complete and biphasic absorption. The half lives of 
the two phases are 14 ± 7 minutes and 4.2 ± 0.9 hrs (mean ± S.D)  
respectively.  The  show  absorption  is  the  rate-limiting  factor  in  
the elimination of  ropivacaine, which is why the terminal half life is 
longer after epidural than after intravenous administration. Ropivacaine 
shows dose proportionality up to the highest intravenous dose studies, 
80 mg corresponding to a mean  ± 1.9 0.3µg/ml. 
 
Distribution 
 
After intravascular infusion, ropivacaine has a steady state 
volume of distribution of 59 ± 7 litres. Ropivacaine is 9.4% protein 
bound, mainly to α1acid glycoprotein. An increase in total plasma 
concentration during continuous epidural infusion has been observed, 
related to postoperative increase of α1acid glycoprotein.     
            Variation in unbound, i.e. pharmacologically active 
concentrations have been less than in total plasma concentrations. 
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Ropivacaine readily crosses the placenta and rapidly equilibrium is 
reached in regard to unbound concentration. 
Metabolism 
Ropivacaine is extensively metabolized in the liver, 
Predominantly by aromatic hydroxylation mediated by cytochrome 
P450 1A to 3 -hydroxy ropivacaine. Approximately 37% of the total 
dose is excreted in the urine as both free and conjugated 3-hydroxy 
ropivacaine have been found in the plasma. 
Urinary excretion of the 4-hydroxyl  ropivacaine have been  
found in  the plasma. Urinary excretion of the 4 - hydroxyl and both 
the 3 - hydroxyl and 4 - hydroxyl N- dealkylated metabolites accounts 
for less than 3% of the dose. An additional metabolite, 2 - hydroxyl 
methyl ropivacaine has been identified but not quantified in the urine. 
Both 3- hydroxyl and 4 - hydroxyl ropivacaine have not quantified in 
the urine. Both 3 - hydroxy and 4 - hydroxy ropivacaine have a local 
anaesthetic activity in animal models less than that of ropivacaine. 
There is no evidence of in vivo racemization in urine of S-(-) 
ropivacaine to R- (+) ropivacaine. 
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Elimination 
The kidney is the main excretory organ for most local anaesthetic 
metabolites. In total 86% of the ropivacaine dose is excreted in the 
urine after intravenous administration of which only 1% relates to 
unchanged drug. Ropivacaine has a mean total plasma clearance of 
387 ± 107 ml/min. The mean ± SD terminal half - life is 1.8 ± 0.7 h 
after intravascular administration and 4.2 ± 1.0 h after epidural 
administration. 
 
 
Pharmocodynamics 
Primary Pharmocodynamics (Animal Studies) 
These studies showed that ropivacaine at low concentration 
produced a profound rapid block of both Aδ and C fibres and was more 
potent than similar low concentrations of bupivacaine. 
At higher concentrations, ropivacaine and bupivacaine had 
similar blocking properties Aδ fibre blocking was 16% greater with 
bupivacaine and the degree of C fibre block was similar with both the 
drugs. 
Ropivacaine is a potent producer of frequency (or use) 
dependant blocks (i.e) a block that occurs only when the fibre is 
stimulated. Ropivacaine  blocks  C  fibres faster than A fibres. 
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Low pKa and high lipid solubility of a local anaesthetic drug 
favoured  A over C fibre block. The lower lipid solubility of ropivacaine 
over bupivacaine is presumed to retard penetration into myelin sheath. 
This greater degree of differential block with ropivacaine at low 
concentration and the property of producing frequency dependent 
block were considered to offer clinical advantages in providing 
analgesia with minimal motor block. 
 
Secondary pharmocodynamics 
Addition of epinephrine to ropivacaine has no limiting effect on 
the systemic absorption of ropivacaine. Systemic absorption can 
produce effects on the  central  nervous  and  cardiovascular  systems.  
At blood  concentration achieved with therapeutic doses, changes in 
cardiac conduction, excitability, refractoriness, contractility and 
peripheral vascular resistance are minimal. However,   toxic   blood   
concentrations   depress   cardiac   conduction   and excitability, which 
may lead to atrio ventricular block, ventricular arrhythmias and to 
cardiac arrest. In addition, myocardial contractility is depressed and 
peripheral vasodilatation occurs, leading to decreased cardiac output 
and arterial blood pressure. 
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Ropivacaine can produce central nervous system stimulation, 
depression or both. Apparent central stimulation is usually manifested 
as restlessness, tremors, shivering, progressing to convulsions,  
followed  by  depression  and coma, progressing to respiratory arrest. 
However, ropivacaine has a primary depressant effect on the medulla 
and on higher centers. The depressed stage may occur without a 
prior excited stage. 
 
Adverse reactions 
A major cause of adverse reactions may be due to excessive 
plasma levels that may be due to over dosage, unintentional 
intravascular injection or slow metabolic degradation. Most adverse 
events reported were mild and transient. 
 
Central nervous system reactions 
These are characterized by excitation and/or depression. 
Restlessness, anxiety, dizziness, tinnitus, blurred vision or tremors may 
occur, possibly proceeding to convulsions. However, excitement 
may be transient or absent with depression being the first 
manifestation. This may quickly be followed by drowsiness, 
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unconsciousness and respiratory arrest. Other effects may be nausea, 
vomiting, chills and constriction of pupils. 
Cardiovascular system reactions 
 
High doses of accidental intravascular injection may lead to high 
plasma levels and related depression of myocardium, decreased cardiac 
output, heart block, hypertension, bradycardia and ventricular 
arrhythmias including ventricular tachycardia and ventricular 
fibrillation and possibly cardiac arrest. 
Preparations available 
0.2% 
 
0.5% 
 
0.75% 
 
1% 
 
 
Uses : 
1.  Infiltration Anaesthesia 
2.  Peripheral Nerve Blocks 
3.  Brachial Plexus Block 
4.  Lumbar Extradural Block (Especially Labour) 
5.  Subarachnoid Block 
6.  Caudal Block. 
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PHARMACOLOGY OF CLONIDINE 1,6 
INTRODUCTION: 
Clonidine hydrochloride is a centrally acting selective partial 
alpha – 2 agonist introduced in early 1960s, it was during its use as a 
nasal decongestant  that its anti - hypertensive property was found out. 
Subsequently more insights  into the pharmacological properties has led 
to its use in clinical anaesthesia  practice as well. 
Clonidine hydrochloride is an imidazoline compound and exists 
as a mesomeric compound. The chemical name is 2 - (2, 6-
dichlorophenylamino) - 2 imidazoline hydrochloride. The structural 
formula is C9 H9 C12 N3 HCI. 
The molecular weight is 266.56. Clonidine is an odourless, 
bitter, white, crystalline substance, soluble in  alcohol  and  water.  
Clonidine improves  the quality of anaesthesia, provides  a more  
stable cardiovascular course during anaesthesia, presumably because 
of their sympatholytic effect and need for lower dose of 
cardioactive anaesthetic and reduces the dose requirement of the 
anaesthetic agent. Clonidine may reduce the halothane MAC by upto 
50% in a dose dependent manner. Clonidine potentiates the anaesthetic 
 34 
 
action of the local anaesthetics with fewer side effects in peripheral 
nerve blocks and central neuraxial blockade. 
                                
 
CLONIDINE HYDROCHLORIDE 
Available as one ml ampoule containing 150 micrograms. It 
should be stored below 25 degree celsius. 
Mechanism of action: 
Clonidine is a centrally acting partial α2 adrenergic agonist with 
a selectivity ration of 220:1 in favour of α2 receptors. The three 
subtypes of α2 receptors are α2a, α2b, α2c, α2a receptors mediate   
sedation, analgesia, sympatholysis. α2b receptors mediate 
vasoconstriction and anti- shivering. The startle response may reflect 
the activation of α2c receptors. The drug is lipid soluble, penetrates  the  
blood  brain  barrier  to  reach  the  hypothalamus  and medulla when 
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injected epidurally. It stimulates the inhibitory α2 adrenoreceptors to 
reduce the central neural transmission in the spinal neurons Inhibition 
of substance-P release is believed to be involved in the analgesic 
effect. 
The α2 adrenoreceptors are located on the afferent terminals 
of both peripheral and spinal neurons in the superficial laminae of the 
spinal cord and within several brain stem nuclei implicated in 
analgesia. The superficial lamiae contain three groups of neurons: 
tonic, adapting, single- spike firing, all of which receive their primary 
sensory input  from  Aδ and C fibres.  
Clonidine inhibits voltage gated sodium and potassium channels 
and suppresses the generation of action potentials in tonic - firing 
spinal dorsal horn neurons, contributing to analgesic effect. The ability 
of clonidine to modify the function of potassium channels in the CNS 
(Cell membrane become hyperpolarized) may be the mechanism for 
profound decrease in anaesthetic requirements. 
Another contribution to analgesic effect may be through the 
release of acetylcholine in the neuraxial region. The two adrenergic 
agonists also enhance analgesia from intraspinal opioids. Sedation is 
produced by its action on locus ceruleus. 
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Clonidine affects the blood pressure in a complex fashion after 
neuraxial or systemic administration because of opposing action at 
multiple sites. In the nucleus tractus solitaries and locus ceruleus of the 
brainstem, activation of post-synaptic α2 adrenoreceptors reduces 
sympathetic drive. 
It also activates nor-adrenergic imidazoline  preferring  binding  
sites  in  the  lateral  reticular nucleus producing hypotension and anti-
arrythmogenic ation. In the periphery, it acts on pre-synaptic α2 
adrenoreceptors at sympathetic terminals reducing the release of  nor-
epinephrine  causing  vasorelaxation  and  reduced  chronotropic drive. 
The brainstem and the peripheral effects of α2 adrenoreceptor 
stimulation are counterbalanced by the direct peripheral 
vasoconstriction through its action on α2 adrenoreceptors from the 
circulating concentrations of clonidine. 
Sedation  is  a  desired  property.  Clonidine  produces  a  dose  
dependent sedation  at  the  dose  of  50  micrograms  or  more  in  less  
than  20  minutes regardless of the route of administration. 
Clonidine doesn’t induce profound respiratory  depression  even  
after massive overdose nor do potentiate respiratory depression from 
opioids. 
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In  peripheral  nerves  it  produces  a  minor  degree of blockade  
at  high concentrations with some preference for C-fibres in the 
peripheral nerves and this effect in part enhance the peripheral nerve 
block when added to local anaesthetics, probably because the α2 
adrenoreceptors are lacking on the axons of peripheral nerves. 
 
Pharmacokinetics: 
 
Clonidine is well absorbed orally and is nearly 100% bio-
available and reaches peak plasma concentration within 60 to 90 
minutes. The mean half life of the drug in plasma is about 9 to 12 
hours, with approximately 50% metabolized in the liver whereas is it 
is excreted in an unchanged form by the kidney, and its half- life can 
dramatically increase in the presence of impaired renal function. 
A transdermal delivery system is available in which the drug is 
released at a constant rate for about a week. Three or four days are 
required to achieve steady state concentration. 
          Clonidine is highly lipid soluble and readily gets distributed into   
extra-vascular sites including the central nervous system. 
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300 micrograms intravenously over 10 min produces:  
Distribution t ½                     :    11 ± 9 minutes 
  Elimination t ½                     :    9 ± 2 hours, 41 hours in severe renal 
 dysfunction.  
Volume of distribution          :    2.1± 0.4 l/kg 
Plasma protein binding         :    20 - 40% in vitro 
 
 
Metabolism                            :   minor pathways with the major        
   metabolite, P - hydroxyclonidine. 
Excretion: 
70% of the dose, mainly in the form of unchanged parent drug 
(40 - 60%) in urine. So, the elimination t ½ of clonidine varies as a 
function of creatinine clearance. In subjects undergoing hemodialysis 
only 5% of the body clonidine store was removed. 
Dosage regimen: 
Oral                          - 3-5µg/kg 
Intramuscular             - 2 µg/kg 
Intravenous              - 1-3µg/kg 
Spinal                      - 50 -100µg  
Epidural                    - 1-2µg/kg 
Transdermal            - 0.1-0.3 mg released per day. 
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Precautions: 
 
1.  In patients with renal insufficiency, lower dose is needed. 
 
2.  Sudden withdrawal of prolonged continuous epidural infusion 
produces hypertensive crisis. So it should be gradually 
discontinued over 2 to 4 days. 
3.  To be used with caution in patients with cerebrovascular or 
coronary insufficiency. 
4.  If  a  patient  with  beta  blocker  is  on  continous  epidural  
therapy, beta blocker should be withdrawn several days before 
discontinuation of epidural clonidine. 
 
Contraindications: 
 
1.  Known hypersensitivity to clonidine or components of the 
product. 
 
2.  In patients with brady arrhythmia or AV block 
 
3.  Patients with severe cardiovascular disease 
 
4.  Patients with cardiovascular / hemodynamic instability. 
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Interactions: 
 
1. Clonidine may potentiate the CNS-depressive effect of 
alcohol, barbiturates or other sedative drugs. 
2.   Narcotics may potentiate the hypotensive effects of clonidine. 
 
3. Tricyclic anti depressants may antagonize the hypotensive effects 
of clonidine. 
4. Concomitant administration of drugs with a negative 
chronotropic and dromotropic effect (beta blocker, digoxin) can 
cause or potentiate bradycardiac rhythm disturbances. 
5.  Beta  blockers  may  potentiate  the  hypertensive  response  
seen  with clonidine withdrawal. 
6.  Epidural clonidine may prolong the duration of pharmacologic 
effects of epidural local anaesthetics, opioids, neostigmine and 
other drugs. 
Uses 
1)     Pre anaesthetic medication  
              a) Oral clonidine (5 µg /kg) blunts reflex tachycardia 
associated with direct laryngoscopy for intubation of 
trachea, 
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              b) Decrease intraoperative lability of blood pressure and  heart 
rate. 
              c) Decrease plasma catecholamine concentrations. 
               d)Dramatically  decrease  anaesthetic requirements for  inhaled 
and  injected anaesthetic. Clonidine also attenuates the rise in 
intraocular pressure associated with laryngoscopy and 
intubation. 
2)     Epidural block : Clonidine as a sole agent or in combination with 
opioids or local  anaesthetics to provide excellent  analgesia  in  
labour analgesia. Epidural clonidine is also indicated for the 
treatment of intractable pain, which is unresponsive to 
maximum does of oral epidural opioid, as do patients with reflex 
sympathetic dystrophy, neuropathic pain. 
3)     Spinal anaesthesia: Clonidine combined with local anaesthetic 
solution, improves the quality and duration of the block, 
minimize the tourniquet pain during lower limb surgery, and 
prevents shivering. 
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4)    Caudal anaesthesia: Clonidine combined with local anaesthetic 
solution, increases the duration of anaesthesia and analgesia by 
two or three times without hemodynamic side effects. Dose 2-3 
µg /kg 
 5)   Peripheral nerve blocks: Clonidine prolongs the duration of 
anaesthesia and analgesia with local anaesthetics by two times in 
a dose of 75 to 150 micrograms. 
6)     Bier’s Block : 150 microgram  of clonidine enhances the   
tolerance of tourniquet 
 
7)       It is also used in intra articular analgesia 
 
8)     Protection against perioperative myocardial ischemia: clonidine 
decreases myocardial ischemia, infarction and mortality   
following cardiovascular surgery. 
9)      To treat hypertensive crisis 
10)     Diagnosis of pheochromocytoma: 0.3 mg will decrease the plasma 
concentrations of catecholamine in normal patients but not in the 
presence of pheochromocytoma. 
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11)    Treatment of shivering: Administration  of  clonidine, 75µg  IV 
stops shivering by inhibiting thermoregulatory control. 
12)    Treatment of opioid and alcohol withdrawal syndrome. 
 
Side effects; 
1.  The most common side effects are sedation and xerostomia 
 
2.   Cardiovascular complaints are bradycardia, hypotension, and ECG 
abonormalities like sinusnode arrest and junctional bradycardia. 
High degree AV block and arrhythmia are reported rarely. 
Occasionally require treatment of bradycardia with IV 
anticholinergics. Orthostatic hypotension occurs rarely. 
3.   Rebound hypertension: Abrupt discontinuation of clonidine can 
result in rebound hypertension as soon as 8 hours and as late as 
36 hours after the last  dose.  Symptoms  of  nervousness,  
diaphoresis,  headache,  abdominal pain, and tachycardia often 
precede the actual increase in systemic blood pressure. Labetalol is 
useful in treatment of rebound hypertension. 
4.   Skin rashes occur frequently. 
 
5.  Impotence occurs occasionally. 
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Over dosage and treatment : 
 
There is no specific antidote for clonidine overdosage. 
Supportive measures like atropine, ephedrine, and IV fluids are 
enough. Yohimbine partially reverses the analgesia and sedation but 
not the blood pressure and heart rate changes produced by the epidural 
clonidine. 
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REVIEW OF LITERATURE 
 
1) Gupta K et al11, in 2014 conducted a randomized double 
blinded study, to evaluate the efficacy of clonidine as an adjuvant to 
0.75% ropivacaine. 64 patients of ASA physical status I and II, between 
18 to 54 years age, scheduled for upper extremity surgery under 
ultrasound guided supraclavicular brachial plexus block were recruited. 
The patients were randomly divided into two groups of 32 each. Group R 
(Ropivacaine) received 19.8ml of 0.75% ropivacaine with 0.2ml of 
normal saline and group RC (Ropivacaine – Clonidine ) received 19.8ml 
of 0.75%  ropivacaine with 0.2ml (30microgram) of clonidine .  
The onset and duration of sensory and motor blockde, the post 
operative analgesia were compared along with monitoring of 
heamodynamic variablity, sedation and other adverse effects. The onset 
of sensory and motor block was significantly faster in group RC than 
group R. The duration of sensory block was 673.9 ± 35 minutes in group 
RC when compared to 535.39 ± 25 minutes in group R. The duration of 
motor block was 614.5 ± 29 minutes in group RC and 485.1 ± 30 
minutes in group R . Both were prolonged in group RC. (p <  0.05 )  
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The duration of analgesia was 956.4 ± 38 minutes in group RC 
and 736.53 ± 47 minutes in group R. Significantly prolonged duration of 
analgesia was observed in group RC ( p <  0.05 ). No side effects were 
observed in both groups . 
 Hence they concluded that addition of 0.2ml (30microgram) of 
clonidine as an adjuvant to 19.8 ml of 0.75% ropivacaine enhanced the 
onset of motor and sensory block, increased the duration of motor and 
sensory blockade and post operative analgesia without any adverse 
events. 
 
 
2) Sirohiya P et al12, in 2016, conducted a randomised double 
blinded study to evaluate the effect of clonidine added to local 
anaesthetic to improve nerve blocks by reducing the time of onset and 
extending the post operative analgesia. 60 patients of ASA physical 
status I and II, between 18 to 60 years of age undergoing upper limb 
surgeries were recruited. The brachial plexus were identified using a 
nerve stimulator. The patients were randomly divided into two groups of 
30 each. Group B (n = 30) received 25 ml of 0.5% bupivacaine and 
0.2ml of normal saline. Group C received 25 ml of 0.5% bupivacaine 
and 0.2ml (30 microgram) of clonidine.  
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The onset of sensory and motor block was significantly faster in 
group C than group B. The duration of sensory block was 474.3 ± 166.6 
minutes in group C when compared to 280.5 ± 101.7 minutes in group B. 
The duration of motor block was 515.3 ± 174.6 minutes in group C when 
compared to 307.5 ± 103.3 minutes in group B. Both were prolonged in 
group C ( p < 0.001). The duration of analgesia was 550.1 ± 182.5 
minutes in group C and 331.0 ± 98.4 minutes in group B. Significantly 
prolonged duration of analgesia was observed in group C (p < 0.001).  
No side effects were observed in both groups. 
Hence they concluded that addition of 0.2ml (30 microgram) of 
clonidine as an adjuvant to 25ml of 0.5% bupivacaine had faster onset of 
motor and sensory block, increased the duration of motor and sensory 
blockade and post operative analgesia without any adverse events.  
 
3) Patil K N et al13, in 2015, conducted a randomized double blind 
study, to assess the characteristics of supraclavicular brachial plexus 
block using 0.75% ropivacaine and the effect of clonidine as an adjuvant. 
The study was conducted on 60 patients between age group 18 and 60 
years, and ASA status I and II, undergoing elective upper limb 
orthopedic surgeries. A nerve stimulator was used to locate the brachial 
plexus. The patients were randomly divided into two groups of 30 each. 
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Group I received 30 ml of 0.75% ropivacaine and 1 ml normal saline. 
Group II received 30 ml of 0.75% ropivacaine and 1 mcg/kg clonidine 
diluted to 1 ml with normal saline. The time taken for onset of sensory 
and motor block, duration of motor and sensory block, duration of 
analgesia and side effects were noted. The onset of sensory and motor 
block was significantly faster in group II than group I. The duration of 
sensory block was 703 ± 42.90 minutes in group II  when compared to 
556.38 ± 37.96 minutes in group I. The duration of motor block was 
621.67 ± 46.76 minutes in group II and 500.86 ± 44.58 minutes in group 
II. Both duration of motor and sensory block were prolonged in group II. 
The difference was statistically significant ( p < 0.001). The mean 
time for rescue analgesia in group I was 613.10 ± 51.797 minutes and in 
group II was 878.33 ± 89.955 minutes. Significantly prolonged duration 
for rescue analgesia was observed in group II ( p < 0.001). No side 
effects were observed in both groups. 
Hence they concluded that 0.75% ropivacaine used in brachial 
plexus block provides effective anaesthesia and post operative pain 
relief. Clonidine as an adjuvant enhances the quality of block by 
providing faster onset, prolonged duration of sensory and motor block 
and improved postoperative analgesia without associated adverse effects. 
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 4) Chakraborthy S et al14, in 2010, conducted a randomized 
double blind placebo controlled trial to evaluate the effect of clonidine as 
an adjuvant to bupivacaine in supraclavicular brachial plexus block. The 
trial was done with 70 patients of ASA grade I and II physical status, 
aged 18 to 60 years, undergoing upper limb orthopedic procedures using 
a nerve stimulator. Group A (n=35) patients received 25 ml of 0.5% 
bupivacaine and 0.2 ml (30 mcg) clonidine. Group B (n=35) received 25 
ml of 0.5% bupivacaine and 0.2ml normal saline.  
The onset of motor and sensory block was faster in group A. The 
duration of motor block was prolonged in group A (330.4 ± 31.6 
minutes) when compared to group B (144.8 ± 17.31 minutes). The 
duration of sensory block was also prolonged in group A (279.1 ± 28.98 
minutes) when compared to group B (116.0 ± 17.1 minutes). All patients 
were observed in postanaesthesia care unit and received Inj.Tramadol as 
rescue analgesic. Analgesia duration was 415.4 ± 38.18 minutes in group 
A when compared to 194.2 ± 28.74  minutes in group B .  
Sedation score was higher in  group A (2.4 ± 0.75) than group B 
(1.7 ± 0.53) but no significant difference was observed in heart rate, 
blood pressure, and oxygen saturation between the two groups. 
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 Hence they concluded that addition of small dose of clonidine (30 
microgram) to 0.5% bupivacaine significantly prolonged the duration of 
analgesia without producing any clinically important adverse reaction 
other than sedation 
 
5) Singh S et al15, in 2010, conducted a randomized controlled 
double blinded study to evaluate the efficacy of clonidine added to 
bupivacaine as compared with bupivacaine alone in supraclavicular 
brachial plexus block for upper limb surgeries. Fifty patients, ASA 
physical status I-III, 18years of age or older, undergoing surgery of the 
upper limb were recruited. In this study, two groups (n=25) were 
investigated. Group I (Bupivacaine-Clonidine) received 40 ml of 
bupivacaine 0.25% plus 0.150 mcg of clonidine and group II 
(Bupivacaine) received 40 ml of bupivacaine 0.25% plus 1 ml of Nacl 
0.9%.  
It was observed that the addition of clonidine to bupivacaine 
resulted in faster onset of sensory block, longer duration of analgesia 
(visual analogue score), prolongation of motor block (Modified Lovett 
Rating Scale) prolongation of recovery of sensation, no haemodynamic 
changes (heart rate and blood pressure), sedation and adverse effects.  
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Hence they concluded that clonidine added to bupivacaine is an 
attractive option for improving the quality and duration of 
supraclavicular block in upper limb surgeries. 
 
6)A.H.Elsaied et al16, in 2000 ,conducted a randomized double 
blind study, to evaluate the effect of adding clonidine to ropivacaine for 
axillary brachial plexus blockade on the onset and duration of sensory 
and motor block and  the duration of analgesia. In this study, 50 patients 
were randomly allocated in two groups, brachial plexus blockade was 
performed using 40ml of ropivacaine 0.75%. Group A, received 150 µg 
clonidine and group B received 1ml of normal saline added to the local 
anesthetic.  
In clonidine group, patients, showed an increased duration of 
sensory loss from 489 minutes to 628 minutes with mean difference of 
138 minutes, motor blockade from 552 minutes to 721 minutes with a 
mean difference of 170 minutes, and analgesia from 587 minutes to 828  
minutes with mean difference of 241 minutes. No side effects were 
noted.  
Hence they concluded that the addition of 150 µg of clonidine to 
ropivacaine for brachial plexus blockade, prolongs the motor and  
sensory block and analgesia without an increased incidence of side effect 
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         7) Eledjam jj et al17, in 1991, conducted a randomized double blind 
study to compare the duration of analgesia produced by addition of 
clonidine with that produced by epinephrine when injected with 
bupivacaine into the  brachial plexus sheath. The study was conducted 
on 60 patients above 18 years of age with ASA status I–II undergoing 
surgical procedures of upper limb using the supraclavicular technique for 
brachial plexus block. The patients were randomly allocated into two 
groups of thirty patients each. Brachial plexus blockade was performed 
using 0.25% bupivacaine. The volume of bupivacaine was determined 
according to the bodyweight (BW) of the patients. 40 ml (100mg) if BW 
<60kg, 45 ml (112.5mg) if  BW < 75 kg , 50 ml (125 mg) if BW > 75 kg. 
Patients in Group I (n=30) received 0.2 mg epinephrine and those in 
Group II (n=30) received 0.15 mg clonidine. Duration of motor blockade 
was prolonged in clonidine group (580.4 ± 38.7 min) when compared to 
adrenaline group (290.6 ± 34.5minutes). The total duration of effective 
analgesia produced with addition of clonidine was longer (994.2 ± 34.2 
minutes) and superior than with adrenaline group (728.3 ± 35.8 minutes).  
Hence they concluded that the injection of clonidine into the 
brachial plexus sheath is an attractive alternative to epinephrine to 
prolong the duration of analgesia in upper limb surgery under conduction 
anaesthesia 
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CLONIDINE AND ROPIVACAINE IN OTHER REGIONAL 
PROCEDURES 
 
8) Cucchiara G et al 19, in 2007, evaluated the effects of clonidine 
on the duration of sensory and motor block and analgesia time in 
children who underwent a variety of peripheral nerve blocks. It reviewed 
the regional anaesthesia database that contain data on children who 
underwent an infraclavicular, lumbar plexus, femoral, fascia illaca or 
sciatic nerve block for post operative analgesia at The Children’s 
Hospital of Philadelphia between October 2002 and December 
2005.Patients were prospectively followed after the nerve block .Two 
hundred fifteen patients (47%) received either bupivacaine or 
ropivacaine local anaesthetics (LA) and 220 (53%) a combination of 
local anaesthetics and clonidine (LAC).The duration of sensory block 
was significantly longer in children who received clonidine with local 
anaesthetics (17.2 ± 5 h) when  compared to children who received local 
anaesthetics alone (13.2±5 h). The difference was statistically significant 
(p=0.0001).The increase in duration was independent from the type of 
peripheral nerve block, local anaesthetics used and operation performed. 
Hence they concluded  that addition of clonidine to bupivacaine 
and ropivacaine can extend sensory block by few hours and increase the 
duration of motor blocks. 
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          9) Casati Andrea MD et al20, in 2000, conducted a randomized 
double blinded study to evaluate the effect of adding  small dose of 
clonidine of to 0.75% ropivacaine during peripheral nerve blocks. 30 
ASA physical status I and II patients undergoing hallux valgus repair 
under combined  sciatic-femoral nerve block were randomly allocated to 
receive block placement with 30 ml of either 0.75% ropivacaine alone 
(group ropivacaine, n=15) or 0.75% ropivacaine plus 1mcg/kg clonidine 
(group ropivacaine–clonidine, n=15). Hemodynamic variables, oxygen 
saturation, level of sedation , time required to achieve surgical block and 
time to first analgesic request were recorded. Time to surgical blockade 
required 10 min in both groups. No difference in oxygen saturation and 
hemodynamic variables, degree of pain measured at first analgesic 
request and post operative analgesic requirement were observed between 
the two groups. The mean time from block placement to first request for 
pain medication was shorter in ropivacaine group (13.7h –17.8 h). The 
difference was statistically not significant (p = 0.038) 
Hence they concluded that adding 1mcg/kg clonidine to 0.75% 
ropivacaine provided a 3hr delay in first request for pain medication after 
hallux valgus repair, with no clinically relevant side effects. 
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10) Gajendra Singh et al10, in 2014, conducted a prospective 
randomized, comparative study in 60 patients to compare the efficacy of 
ultrasound guided supraclavicular block with conventional (blind) 
technique eliciting paresthesia. Block was performed using 15 ml 0.5% 
bupivacaine and 15 ml of 2% lignocaine with adrenaline in both groups. 
They found that the success rate of block was more with ultrasound  
group than the conventional technique. Time taken for a block performed 
by ultrasound was shorter than the conventional technique. Also the 
duration of analgesia was longer and very fewer complications were 
reported in ultrasound group when compared to the conventional 
approach. 
 
11)Dr. Shweta S. Mehta et al7, in 2015, conducted a study to 
compare ultrasound guided with peripheral nerve stimulator induced 
technique for supraclavicular brachial plexus block in 50 patients with 
0.5% sensorcaine 25-35ml. They concluded that ultrasound guided 
method is an improved nerve block technique due to visualization of 
nerves with more success, decreased complication rate, faster onset, and 
less time consuming as compared to nerve stimulation. 
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12) Vincent W. S. Chan et al8, in 2003, conducted a study to 
evaluate state-of-the-art ultrasound technology for supraclavicular 
brachial plexus blocks in 40 outpatients. In this study, the block was 
successful after one attempt in 95% of the cases, with one failure 
attributable to subcutaneous injection and one to partial intravascular 
injection without incidence of pneumothorax. 
 
13) Leslie C. Thomas et al9, in 2011, conducted a prospective, 
randomized study in 41 patients with inexperienced anesthesia residents 
to compare differences in ultrasound and nerve stimulation guided  
interscalene brachial plexus block. They concluded that the use of 
ultrasound technology in an academic medical center facilitates safe, 
cost-effective and quality care.  
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MATERIALS AND METHODOLOGY 
 
Study Design  :  Prospective Single Blinded Case Control Study 
Sample Size   :  64 patients 
Sampling Method  :  Randomised sampling 
Statistical Analysis           : Statistical analysis was done using SPSS 
software (version 20).Baseline variables 
between the two groups were compared using 
Chi-square test. 
Method of collection        :  All patients undergoing elective upper limb   
Surgery 
 
After obtaining approval from the institutional ethical committee, 
Thanjavur Medical College, Thanjavur, the study was conducted in 64 
ASA I or ASA II patients, aged between 18 to 58 years undergoing 
elective upper limb surgeries under ultrasound guided supraclavicular 
block. Before including the patients for the study, all patients were 
explained about the procedure and written informed consent was taken 
from the patient and the patient’s attenders. Result values were recorded 
using a preset proforma. 
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INCLUSION CRITERIA: 
    1.   ASA grade I or II patients 
      2.   Elective upper limb surgeries 
                                              3.   Patients of either sex, between 18 – 58 years of age 
EXCLUSION CRITERIA: 
1. Patient’s  refusal 
2. Patients <18 years and >58 years of age  
3. Patients with coagulopathy or peripheral neuropathy 
4. ASA grade III or IV patients 
5. Allergy to local anaesthetics 
6. Inability to locate the brachial plexus accurately on 
ultrasound 
 
         7.  Patients on adrenergic and psychotropic medication 
          8.  Patients with a history of pre-existing cardiac or   
               Pulmonary disease 
 
          9. Patients who needed general anaesthesia after                             
unsuccessful block 
 
         10. Patients receiving chronic analgesic therapy  
Each patient was randomly allocated into one of the two groups of 
32 patients each  
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In Group R:         
           Patients received supraclavicular block with 19.8 ml of 0.75%  
ropivacaine + 0.2 ml normal saline 
In Group RC:    
           Patients received supraclavicular block with 19.8ml of 0.75% 
ropivacaine + 0.2ml (30 microgram) clonidine 
Care was taken to avoid any local anesthetic toxicity and 
intravascular injection. No premedication was given to the patients. 
Anaesthesia machine checked, resuscitative equipments and drugs were 
kept ready. Intravenous access secured, ringer lactate started at 4ml/kg/hr 
in all patients and continuous monitoring of pulse rate, non invasive 
blood pressure, electrocardiogram was ensured.  
Patients were made to lie down in supine position with head 
turned to contralateral side and ipsilateral arm adducted gently and 
shoulder kept down with flexed elbow. After sterile preparation, the 
brachial plexus was visualized with a 38 mm 8 -13 MHz linear high 
frequency ultrasound transducer placed in saggital plane in the 
supraclavicular fossa behind the middle third of the clavicle. 
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          The brachial plexus appeared as 3 hypoechoic circles with 
hyperechoic outer rings or as grape like cluster located lateral and 
superior to subclavian artery between the anterior and middle scalene 
muscles at lower cervical region. The predicted volume of 20 ml of drug 
solution was administered around brachial plexus after negative 
aspiration to avoid accidental intravascular needle puncture. 
 
 PARAMETERS OBSERVED 
   1.Onset of sensory blockade: 
          It was defined as the time interval between the end of local 
anaesthetic administration and complete loss of sensation (Score 0). It 
was assessed by pinprick test along the distribution of each nerve with a 
needle using a 3 point scale for pain 
 0 – Loss of sensation to touch (Anaesthesia) 
 1 – Loss of sensation to pin prick (Analgesia)  
 2 – Normal sensation        
and compared to same stimulation on contralateral arm. 
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2. Onset of motor blockade: 
                 It was defined as the time interval between total local 
anaesthetic administration and complete motor block (Grade 2). It was 
assessed by thumb abduction (radial nerve), adduction (ulnar nerve), 
and opposition (median nerve) according to Modified Bromage Scale. 
Grade 0 -  Normal motor function with full flexion and extension of 
elbow ,wrist and  fingers. 
Grade 1 -   Decreased motor power with the ability to move the fingers   
only. 
Grade 2 – Complete motor block with inability to move the fingers. 
3.Duration of surgery: 
                 It was defined as the time taken from skin incision to skin  
closure. 
4.Duration of motor blockade: 
                  It was defined as the time interval from complete motor 
block to complete recovery of motor function of hand and forearm 
(Grade 0) Modified Bromage Scale. 
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5. Duration of sensory blockade: 
                   It was defined as the time interval between the complete 
sensory block and complete resolution of anaesthesia on all the nerves 
(Score 2). 
6. Duration of analgesia: 
                   It was defined as the time between the complete sensory 
block and the first analgesic request. It was assessed using 10 point 
visual analogue scale having 10 cm length numbered from 0 to 10. 
Patient was explained about the visual analogue scale as  
0 – No pain and 10 the worst possible pain and was asked the score in 
visual analogue scale. 
Pain was assessed at 2, 4, 6, 8, 12, and 16 h and Injection Tramadol 
(100mg) was used as rescue analgesic on patient’s demand. 
7.Vital parameters 
                 Heart rate, Blood pressure, Oxygen saturation were 
monitored  at  0, 2, 5, 10, 15, 30, 60 mins, and  2, 3, 6, 12, 24 hrs 
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Sedation Score 
Ramsay Sedation Score was employed 
1.Anxious and alert 
2.Conscious and oriented 
3.Sedated, responding to verbal stimulus 
4.Responding to mild physical stimulus 
5.Responding to moderate and severe physical stimulus 
6.Not arousable 
8.Side effects :                                                                                                                
               Hypotension, bradycardia, shivering, nausea, vomiting,  and 
other side effects were noted 
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OBSERVATIONS AND RESULTS 
 
The information collected regarding all the selected cases were 
recorded in a Master Chart. Data analysis was done with the help of 
computer using Epidemiological Information Package. 
Using this software range, frequencies, percentage, means, 
standard deviation, chi square and p value were calculated. Student’s t 
test was used to test the significance of difference between quantitative 
variables and Yate’s chi square test for qualitative variables. A p value 
less than 0.05 is taken to denote significant result. 
This study comprised of two groups. The patients in group R 
received 0.75% ropivacaine 19.8ml + 0.2ml normal saline. In group RC 
received 0.75% ropivacaine 19.8ml + 30 microgram of clonidine. 
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1.Age 
Age distribution in the group R varied from 18years to 58years 
with mean age of 34.7years and standard deviation of 12.3 
In group RC age varied from 18years to 58years with mean value of 
34.5 years and standard deviation 13.05 as shown in table I Fig 1 
 
 
Table :1: Age Distribution 
 
 
Age in years 
Group R Group RC 
No % No % 
Up to 20 years  5 15.6 5 15.6 
21-30 years  9 28.1 11 34.3 
31-40 years  6 18.7 6 18.7 
41-50 years  7 21.8 5 15.6 
Above 50 years  5 15.6 5 15.6 
Total  32 100 32 100 
Mean ± S.D  34.72 ± 12.38 34.50 ± 13.05 
p value 0.945 > 0.05 (Not significant) 
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2. Sex  
 
 
 
Table :2 
Sex Group R Group RC No % No % 
Male 26 81.3% 21 65.6% 
Female 6 18.8% 11 34.4% 
Total 32 100 32 100 
p value 1.57>0.05( Not significant) 
 
Fig 2 
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In group R 26 were male and rest were female 
In group RC 21 were male and rest were female as shown in Table 2 Fig 2 
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3.Weight  
Weight in the group R had a mean value of 49.47 kgs with 
standard deviation of 5.25 
 Weight in group RC had a mean value of 47.31 kgs with standard 
deviation of 5.67 as shown in Table 3 Fig 3 
Table 3 
Weight (in kgs) Group R Group RC 
Range 42 – 60 kgs 35 – 58 kgs 
Mean        49.47 kgs           47.31 kgs 
S.D        5.25           5.67 
‘P’ 0.120> 0.05  Not significant 
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4. ASA Status 
In group R 27 patients were ASA I and 5 patients were ASA II 
In group RC 27 patients were ASA I and 5 patients were ASA II as 
shown in Table 4 Fig 4 
Table 4 
ASA Status 
Group R Group RC 
No % No % 
I 27 84.4% 27 84.4% 
II 5 15.6% 5 15.6% 
Total 32 100 32 100 
p value 1.000>0.05  Not significant 
 
Fig 4 
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5.Onset of sensory block: 
 
Time taken for the onset of sensory blockade in group R 
varied from 8 minutes to a maximum of 9 minutes with a mean value 
of 8.6 minutes and with a standard deviation of 0.50.  In group RC it 
varied from 4 to a maximum of 9 minutes with a mean value of 4.4 
minutes and standard deviation of 0.50  as shown in Table 5 Fig 5 
 
Table 5: Onset of sensory block (in mins) 
Onset of 
sensory block 
(in minutes) 
Group R Group RC 
Range  8 – 9 min 4 – 9 min 
Mean  8.56  min         4.43 min 
          S.D        0.50          0.50    
    p value .000 < 0.05 significant 
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Fig.5 
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6. Onset of motor Block  
 
 
Onset of motor block varied from 10 minutes to 11 minutes in 
group R with a mean value of 10.50 minutes and standard deviation of 
0.50 . 
 In group RC it varied from 7 minutes to 10 minutes with a mean 
value of 8.46 minutes and standard deviation of 0.76 as shown in Table 6 
Fig 6 
         Table 6: Onset of motor block ( in minutes) 
 
 
 
 
 
 
 
 
Onset of motor 
block (in minutes) Group R Group RC 
 Range 10 – 11 min 7 – 10 min 
Mean     10.50 min       8.46 min 
            S.D      0.50        0.76 
  p value .000<0.05 significant 
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Fig.6 
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7. Duration of sensory block ( in hrs) 
 
The duration of sensory blockade in group R varied from 8 hrs to 
a maximum of 10 hrs with a mean value of 8.93 hrs and a standard 
deviation of 0.59 . 
In group RC varied from 10 hrs to 12 hrs with mean value of 
11.37 hrs and a standard deviation of 0.65  as shown in Table 7, Fig 7 
 
Table 7 : Duration of sensory block ( in hrs) 
Duration of 
sensory block  
(in hrs) 
Group R Group RC 
Range   8 – 10 hrs   10 – 12 hrs 
Mean          8.93 hrs 11.37 hrs 
S.D          0.59               0.65 
p value                   .000<0.05 significant 
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Fig.7 
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8. Duration of motor blockade( in hrs): 
The duration of motor blockade in group R varied from 6 hrs  
to a maximum of 8.5 hrs with a mean value of 7.18 hrs and a 
standard deviation 0.59 . In group RC varied from 9 hrs to 11 hrs 
with a mean value of 9.37 hrs and standard deviation of 0.55 as 
shown in Table 8, Fig 8 
       Table 8: Duration of Motor Blockade 
Duration of 
Motor Block 
(in hrs) 
Group R Group RC 
Range 6 – 8.5 hrs 9 – 11 hrs 
Mean 7.18 hrs 9.37 hrs 
S.D 0.59 0.55 
p value                .000<0.05 significant 
 
Fig  8 
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9: Duration of surgery (in hrs)  
The duration of surgery in group R varied from 1-3 hrs with 
mean of 1.53 hrs and standard deviation of 0.72 .    
In group RC it varied from 1–3 hrs with mean 1.34 hrs and 
standard deviation 0.41 as shown in Table 9, Fig 9 
Table 9: Duration of surgery (in hrs) 
Duration of 
surgery 
 (in hrs) 
Group R Group RC 
Range        1 -3 hrs               1 – 3 hrs 
Mean         1.53 hrs       1.34 hrs 
S.D         0.72  0.41 
p value 0.210<0.05 significant 
 
Fig.9 
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 10: Duration of analgesia 
The mean duration of analgesia in group R was 9.43 hrs with 
standard deviation 0.59. 
In group RC the mean duration of analgesia was 14.10 hrs with 
standard deviation 0.61, as shown in Table 10,Fig 10 
Table 10:Duration of Analgesia 
Group 
Duration of 
analgesia ( in hrs) 
      p value 
Mean ±SD 
Group R 9.43 ± 0.05 
 0.000 < 0.05     
(significant) Group RC 14.10  ± 0.61 
 
Fig.10 
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 11: Sedation score 
In group R the mean sedation score was 2.00 with a standard 
deviation of 0.0  
In group RC the mean sedation score was 2.37 with  a standard 
deviation of 0.49 as shown in Table 11, Fig 11 
 
Table 11 
Sedation 
Score 
Group R Group RC 
No % No % 
2 32 100 20 62.5 
3 - - 12 6.25 
Total  32 100 32 100 
Mean    2.00 2.37 
SD 
 0.0  0.49 
p value .000 < 0.05 significant 
 
Fig.11 
SEDATION SCORE 
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 Hemodynamic variables 
 Pulse rate , systolic BP, diastolic BP, was recorded at intervals of  
0 , 2, 5, 10, 15, 30, 60 mins, 2 hrs, 3 hrs, 6 hrs, 12 hrs and 24 hrs. 
 
Pulse rate 
Table No.  : Pulse rate (beats per min) 
 
 
     Time 
interval(min) 
Pulse rate 
( beats per minute) 
 
 
 
 
 
p value 
 
 
 
 
 
Significance 
 
Group R 
 
Group RC 
 
Mean±S.D 
 
Mean±S.D 
 
0 
 
83.78±12.98 
    
  83.72±12.90                      
 
0.985
 
Not significant 
 
2 
 
82.22±13.25 
 
82.47±12.32 
 
0.938 
 
Not significant 
 
5 
 
80.75±12.44 
 
80.66±12.11 
 
0.976 
 
Not significant 
 
10 
 
80.16±12.46 
 
79.50±11.89 
 
0.830 
 
Not significant 
 
15 
 
79.47±12.04 
 
77.66±11.62 
 
0.542 
 
Not significant 
 
30 
 
78.84±11.45 
 
78.53±11.22 
 
0.913 
 
Not significant 
 
60 
 
78.25±11.39 
 
76.75±10.80 
 
0.591 
 
Not significant 
 
2 hrs 
 
77.59±11.35 
 
76.19±10.62 
 
0.611 
 
Not significant 
 
3 hrs 
 
75.41±10.40 
 
75.19±10.21 
 
0.933 
 
Not significant 
 
6 hrs 
 
76.84±10.39 
 
76.75±10.80 
 
0.972 
 
Not significant 
 
12 hrs 
 
77.28±10.88 
 
76.19±10.62 
 
0.686 
 
Not significant 
24 hrs 75.41±10.401 75.19±10.21 0.933 Not significant 
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PULSE RATE AT VARIOUS TIME INTERVALS 
 
 
 
 In group R, the mean pulse rate ranged from 75.41 to 83.78 beats  
per min. In group RC, the mean pulse rate ranged from 75.19 to 83.72 
beats per min. The statistical analysis by Student’s unpaired ‘t’ test 
showed that there was no  significant difference in pulse between the two 
groups (p > 0.05) 
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Systolic blood pressure 
Table No.  :   Systolic blood pressure (mm / Hg) 
 
 
 
     Time 
interval(min) 
 Systolic blood pressure                                        
(SBP) 
 
 
 
 
 
p value 
 
 
 
 
 
Significance 
 
Group R 
 
Group RC 
 
Mean±S.D 
 
Mean±S.D 
 
0 
 
122.50±9.50 
            
124.56±9.10                      
 
0.379 
 
Not significant 
 
2 
 
123.75±8.70 
 
124.56±9.10 
 
0.716 
 
Not significant 
 
5 
 
123.63±8.77 
 
124.25±8.94 
 
0.779 
 
Not significant 
 
10 
 
123.56±8.73 
 
122.88±8.84 
 
0.755 
 
Not significant 
 
15 
 
122.63±9.26 
 
123.13±8.68 
 
0.824 
 
Not significant 
 
30 
 
121.63±8.73 
 
122.63±9.57 
 
0.664 
 
Not significant 
 
60 
 
121.13±8.72 
 
123.44±8.94 
 
0.299 
 
Not significant 
 
2 hrs 
 
120.38±7.87 
 
125.81±8.26 
 
0.099 
 
Significant 
 
3 hrs 
 
120.88±8.60 
 
126.44±7.94 
 
0.099 
 
Significant 
 
6 hrs 
 
121.13±8.72 
 
123.44±8.94 
 
0.299 
 
Not significant 
 
12 hrs 
 
120.38±7.87 
 
125.81±8.26 
 
0.009 
 
 Significant 
24 hrs 120.88±8.60 126.44±7.94 0.009  Significant 
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SYSTOLIC BLOOD PRESSURE AT VARIOUS TIME 
INTERVALS 
 
 
In group R, the systolic blood pressure ranged from 120.38 to 123.75 
mm /Hg. In group RC, the mean systolic blood pressure ranged from 
122.63 to 126.44 mm/Hg. The statistical analysis by Student’s unpaired 
‘t’ test showed that there was no significant difference in pulse between 
the two groups (p > 0.05) 
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Diastolic blood pressure 
Table No.  :   Diastolic blood pressure (mm / Hg) 
 
 
     Time 
interval(min) 
 Diastolic blood pressure                                        
(DBP) 
 
 
 
 
 
 
p value 
 
 
 
 
 
Significance 
 
Group R 
 
Group RC 
 
Mean±S.D 
 
Mean±S.D 
 
0 
 
75.31±6.21 
        
75.88±4.95                      
 
0.690 
 
Not significant 
 
2 
 
75.31±6.21 
 
75.88±4.95 
 
0.690 
 
Not significant 
 
5 
 
75.31±6.21 
 
75.81±4.90 
 
0.722 
 
Not significant 
 
10 
 
74.88±5.74 
 
75.50±4.68 
 
0.635 
 
Not significant 
 
15 
 
74.63±5.50 
 
 74.19±4.93 
 
0.739 
 
Not significant 
 
30 
 
73.88±5.20 
 
 73.25±4.75 
 
0.618 
 
Not significant 
 
60 
 
73.19±5.27 
 
 72.44±4.59 
 
0.546 
 
Not significant 
 
2 hrs 
 
72.63±5.27 
 
 71.81±4.58 
 
0.507 
 
Not significant 
 
3 hrs 
 
72.81±5.07 
 
 71.31±4.75 
 
0.227 
 
Not significant 
 
6 hrs 
 
72.63±5.14 
 
 71.75±4.78 
 
0.484 
 
Not significant 
 
12 hrs 
 
72.81±5.07 
 
 71.44±4.40 
 
0.252 Not significant 
24 hrs 72.63±5.14  71.31±4.75 0.293 Not significant 
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DIASTOLIC BLOOD PRESSURE AT VARIOUS TIME 
INTERVALS 
 
 
 
In group R , the diastolic blood pressure ranged from 72.63 to 75.31   
mm /Hg. In group RC, the mean diastolic blood pressure ranged from 
71.31 to 75.88 mm/Hg. The statistical analysis by Student’s unpaired ‘t’ 
test showed that there was no significant difference in pulse between the 
two groups (p > 0.05) 
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Saturation time 
Table No.  :   Saturation time 
 
 
 
Time 
interval(min) 
Saturation time                                    
(Spo2) 
 
 
 
 
 
 
p value 
 
 
 
 
 
Significance 
 
Group R 
 
Group RC 
 
Mean±S.D 
 
Mean±S.D 
 
0 
 
99.72±0.52 99.66±0.54 
 
0.641 
 
Not significant 
 
2 
 
99.72±0.52 
 
99.66±0.54 
 
0.641 
 
Not significant 
 
5 
 
99.69±0.53 
 
99.66±0.54 
 
0.818 
 
Not significant 
 
10 
 
99.38±0.55 
 
99.34±0.70 
 
0.844 
 
Not significant 
 
15 
 
99.31±0.59 
 
99.00±0.62 
 
0.440 
 
Significant 
 
30 
 
99.25±0.66 
 
99.81±0.64 
 
0.008 
 
Significant 
 
60 
 
99.09±0.64 
 
98.81±0.64 
 
0.085 
 
Not significant 
 
2 hrs 
 
99.06±0.43 
 
98.63±0.60 
 
0.002 
 
Significant 
 
3 hrs 
 
99.16±0.57 
 
98.94±0.43 
 
0.091 
 
Not significant 
 
6 hrs 
 
99.31±0.59 
 
98.66±0.65 
 
0.000 Significant 
 
12 hrs 
 
99.19±0.59 
 
98.63±0.60 
 
0.000 Significant 
24 hrs 99.06±0.43 98.94±0.43 0.255 Not significant 
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SATURATION AT VARIOUS TIME INTERVALS 
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In group R, the mean saturation ranged from 99.06 to 99.72. In group 
RC, the mean saturation ranged from 98.63 to 99.66. The statistical 
analysis by Student’s unpaired ‘t’ test showed that there was no 
significant difference in pulse between the two groups (p > 0.05) 
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DISCUSSION 
Supraclavicular brachial plexus block is preferred for its rapid 
onset, reliable anesthesia and as a safe technique for any surgery in the 
upper extremity. This is because the block is performed at the level of 
nerve trunks, where, almost the entire innervations of the upper 
extremity are confined to a very small surface area. 
Regional anaesthesia makes a simple demand that the right dose of 
the right drug to be given at the right place. The main challenge of 
regional technique is the unreliability of conventional modalities for 
confirming the nerve localization due to anatomical variation. Nowadays 
ultrasound has improved success rate with excellent localization and 
improved safety margin when compared to nerve stimulation and 
landmark technique. 
Regarding the choice and dosage of the drug  
Ropivacaine is a pure S(−) enantiomer, structurally related to 
bupivacine, developed for the purpose of reducing potential toxicity and 
improving relative sensory and motor block profiles. The efficacy of 
ropivacaine is similar to that of bupivacaine and levobupivacaine for 
peripheral nerve blocks. Ropivacaine with its efficacy, lower propensity 
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for motor block and reduced potential for cardiotoxicity and central 
nervous system toxicity, appears to be an important option for regional 
anesthesia and management of postoperative pain1. 
 Clonidine enhances both sensory and motor blockade of neuraxial 
and peripheral nerves after injection of local anesthetic solutions. There 
have been four proposed mechanisms for the action of clonidine in 
peripheral nerve blocks. These mechanisms are centrally mediated 
analgesia, alpha-2-adrenoreceptor mediated vasoconstriction, attenuation 
of inflammatory response and direct action on peripheral nerve. 
Clonidine possibly enhances or amplifies the sodium channel blocking 
action of local anesthetics by opening up the potassium channels 
resulting in hyperpolarization, a state in which the cell is unresponsive to 
excitatory input 6. 
Many authors support the hypothesis that clonidine exerts its local 
anaesthetic prolonging effect to directly on the nerve fibre, as a result 
complex interaction between clonidine and axonal ion channels. 
Peripheral antinociception induced by clonidine has been related to two 
adrenoreceptor mediated local release of enkephalin like substances6. 
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In our study, patients were randomly divided into two groups of 
32 each, namely group R (Ropivacaine) and group RC (Ropivacaine- 
Clonidine).We had used 19.8ml of 0.75% ropivacaine with 0.2ml (30 
mcg) of clonidine as an adjuvant for brachial plexus block. 
         This dose had not crossed the toxic limit for ropivacaine (3mg/kg). 
The mean weight in Group R was 49.4 ± 5.2  and in group RC it was 
47.3 ± 5.6 
So we have decided to use 19.8ml of 0.75% ropivacaine as the 
local anaesthetic solution. 
In a study conducted by Sirohiya et al, the addition of 0.2ml 
(30microgram) of Clonidine to bupivacaine significantly prolonged the 
duration of post operative analgesia without any complications12. 
Similarly, in a study conducted by Chakraborty et al, the addition 
of small dose of clonidine 0.2ml (30mcg) to local anaesthetic solution 
significantly prolonged the duration of analgesia without producing any 
clinically important adverse reactions14. 
So we have decided to add 0.2ml (30mcg) of clonidine as an 
adjuvant to local anaesthetic solution. 
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Patient Characteristics across the groups 
The patient in our study did not vary much with respect to age, 
sex, weight. The mean age of patients in group R was 34.7 ± 12.3 
whereas in group RC it was 34.5 ± 13.0. The difference between the two 
groups was not statistically significant with a p value of 0.945. The mean 
weight of patients in group R was 49.4 ± 5.2 whereas in group RC it was 
47.3 ± 5.6. The difference between the two groups was not statistically 
significant with a p value of 0.120. When comparing the sex distribution 
in the two groups it was statistically not significant with a p value of 
1.57. When comparing the duration of surgery in the two groups it was 
statistically not significant with a p value of 0.210 . 
Onset of sensory blockade  
In our study, we found that the mean time of  onset of sensory 
blockade in group R was 8.5 ± 0.5 minutes and in group RC it was 4.4 ± 
0.5 minutes. The difference between the two groups was statistically 
significant with a p value of 0.000 ( p < 0.05). 
This observation well matches with study of Patil K N et al, the 
time of onset of sensory block was faster in ropivacaine clonidine group 
(4.36 minutes) than the plain ropivacaine group (4.84 minutes)13. 
 92 
 
In a study conducted by Sirohiya P et al, the time of onset of 
sensory block was faster in  group C (Clonidine) (4.9 minutes) when 
compared to group B (Bupivacaine) (11.6 minutes) .These results 
correlate with our study12. 
Onset of motor blockade 
In our study, we found that the mean time of onset of motor 
blockade in group R was 10.5 ± 0.5 minutes and in group RC it was 8.4 
± 0.7 minutes. The difference between the two groups was statistically 
significant with a p value 0.000 ( p <0.05). 
In a study conducted by Patil KN et al, the onset of motor block 
was significantly faster in ropivacaine clonidine group (9.83 minutes) 
than the plain ropivacaine group (10.85minutes). These results correlate 
with our study13. 
Similar results were observed by Sirohiya P et al. The time of 
onset of motor block was faster in bupivacaine clonidine group ( 6.0 ± 3 
minutes) when compared with plain bupivacaine group ( 22.2 ± 8 
minutes)12. 
Hence it was found by various studies that the addition of 
clonidine to the local anaesthetic solution (Ropivacaine) there was an 
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earlier onset of sensory and motor blockade compared to local 
anaesthetic solution (Ropivacaine) alone.   
Duration of motor blockade 
In our study, we found that the mean duration of motor block in 
group R was 7.18 ± 0.5 hrs and in group RC was 9.37 ± 0.5 hrs. The 
difference between the two groups was statistically significant with a p 
value of 0.000 ( p < 0.05 ). 
According to Gupta et al, the duration of motor block was 
significantly prolonged in group RC (614minutes) compared to group R 
(485minutes). This is concordant with our study11. 
Similarly, in a study conducted by A.H.Elsaid et al, the duration of 
motor block was significantly prolonged in group RC (721minutes) 
compared to group R (552minutes)16.  
         Hence it was found by various studies that the addition of clonidine 
to the local anaesthetic solution prolonged the duration of motor 
blockade 
Duration of sensory blockade 
In our study, we found that the mean duration of sensory block in 
group R was 8.9 ± 0.5 hrs and in group RC was 11.3 ± 0.6 hrs. The 
 94 
 
difference between the two groups was statistically significant with a p 
value of 0.000 ( P < 0.05 ). 
This observation well matches with study of  Gupta et al., the 
duration of sensory block was significantly prolonged in group RC 
(673.9minutes) compared to group R (535.3minutes)11. 
Sirohiya P et al, in his study noted that the duration of sensory 
block was significantly prolonged in clonidine group  (474 minutes) than 
plain bupivacaine group (280 minutes12.  
Hence it was found by various studies that the addition of 
clonidine to the local anaesthetic solution prolonged the duration of 
sensory blockade. 
Duration of analgesia 
In our study, we found that the mean duration of analgesia in 
group R it was 9.4 ± 0.5 hrs and in group RC it was 14.1 ± 0.6 hrs. The 
difference between the two groups was statistically significant with a p 
value of .000 ( p < 0.05 ). 
According to Gupta et al, the duration of analgesia was 
significantly prolonged in group RC (956minutes) compared to group R 
(736 minutes). This is concordant with our study11. 
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Similar results were observed by A.H.Elsaid et al. The duration of 
motor block was significantly prolonged in group RC (828 minutes) 
compared to group R (587 minutes)10. 
Hence it was found that the addition of clonidine to the local 
anaesthetic solution prolonged the duration of analgesia. This is because 
of perineurally injected clonidine exerts an analgesic effect through 
systemic absorption.  
Sedation score 
The sedation score in both groups were noted.  The mean sedation 
score in group R was 2.0,whereas in group RC it was 2.3 .The sedation 
score is significant in group RC compared to group R with a p value o f  
0.000 ( p <  0.05 ). In group RC since the sedation score was not more 
than 3, the respiratory function was not compromised.  
In a study done by Chakraborty et al., the mean sedation score in 
bupivacaine group, was 1.7, whereas in bupivacaine clonidine group, it 
was mean 2.4. This is concordent with our study14. 
Hemodynamics 
In our study, we found that no significant difference was observed 
with respect to the pulse rate, systolic and diastolic blood pressure and 
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saturation after administration of the block, since low dose of clonidine 
0.2 ml ( 30 microgram) was used. 
Chakraborty et al, in their study to evaluate clonidine as adjuvant 
to bupivacaine in brachial plexus block, concluded that no significant 
difference was observed with respect to respiratory rate, systolic 
diastolic blood pressure and saturation between the two groups when 30 
microgram of clonidine was used. This is concordent with our study 14 
Side effects 
In both groups there was no incidence of hypotension, 
bradycardia, shivering, nausea and, vomitting  
Chakraborty et al, in their study to evaluate clonidine as adjuvant 
to bupivacaine in brachial plexus block, concluded that addition of small 
dose of clonidine 0.2 ml (30 mcg) to bupivacaine does not produce any  
adverse reactions. This is concordent our study14. 
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SUMMARY 
 
64 patients of ASA grade I or II undergoing upper limb surgeries 
were randomly assigned into two groups, Group R and RC. 
Surgery was done under supraclavicular approach to brachial 
plexus block with ultrasound guidance 
The patients in group R received 19.8ml at 0.75% ropivacaine and 
0.2 ml normal saline. In group RC patients received 19.8ml at 0.75% 
ropivacaine and 0.2 ml of (30 micrograms) clonidine. 
Parameters observed were time of onset of sensory blockade  
and  motor blockade, duration of motor blockade, and sensory blockade, 
duration of analgesia, sedation score and side effects. 
This study shows that 
1.  Addition of clonidine to ropivacaine shows early onset of sensory 
blockade when compared to ropivacaine alone. 
 2.  Addition of clonidine to ropivacaine shows early onset of motor 
blockade  when compared to ropivacaine alone. 
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3.  Addition of clonidine to ropivacaine significantly prolongs the 
duration of analgesia (14.1 ± 0.6 hrs) when compared to 
ropivacaine alone  (9.4 ± 0.5 hrs) 
4.  Addition of  clonidine to ropivacaine increases the  duration  of  
sensory   blockade ( 11.3 ± 0.6 hrs ) when compared to ropivacaine 
alone  (8.9 ± 0.5 hrs ) 
5.  Addition of clonidine to ropivacaine  increases  the  duration  of  
motor blockade  (9.3 ± 0.5 hrs ) when compared to ropivacaine 
alone    (7.1 ± 0.5 hrs ) 
 6.  In  clonidine  group  intra  operative  sedation  is  well  observed  
without compromising respiratory function. 
7. There were no side effects like hypotension,  bradycardia, 
shivering,  nausea,  vomiting  with  30 microgram of clonidine. 
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                                          CONCLUSION 
 
The addition of clonidine (30 microgram) to local anaesthetic 
solution in ultrasound guided supraclavicular brachial plexus block 
shows early onset of sensory and motor blockade, prolongs the duration 
of sensory and motor blockade and duration of analgesia when 
compared to local anaesthetic solution alone. 
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PROFORMA 
TO EVALUATE THE EFFECTIVENESS OF CLONIDINE AS AN 
ADJUVANTS TO ROPIVACAINE IN ULTRASOUND GUIDED 
BRACHIAL PLEXUS BLOCK 
 Name:                              Age :                       Sex:                       ASA: 
Grade:     Address :                                    Weight :                        
IP No :  Diagnosis : 
Surgery : 
Investigations : 
Hb% : 
Urine 
Albumin 
& Sugar 
Blood urea - 
mg%        
Sugar          - 
mg% 
Creatinine   - 
mg% 
Group R       – 19.8 ml of 0.75% ropivacaine +0.2 ml normal saliene 
Group RC     – 19.8 ml of 0.75% ropivacaine + 0.2 ml (30 mcg) clonidine 
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OBSERVATION: 
Onset of sensory blockade         : 
Onset of motor blockade           :  
Duration of sensory blockade    : 
Duration of motor blockade      :  
Duration of analgesia                 :  
Duration of surgery                   :      
Side effects                                :      
HAEMODYNAMICS 
 0 
mins 
2 
min 
5 
min  
10 
min 
15 
min 
30 
min 
60 
min 
2  
hrs 
3     
hrs 
6 
 hrs 
12 
hrs 
24 
hrs 
PR             
SBP             
DBP             
SPo2             
VAS (Visual Analogue score) 
Sedation Score : Ramsay sedation Score was employed 
       1.  Awake & Alert 
       2.  Conscious and oriented 
       3.  Sedated responding to verbal stimulus 
       4.  Responding to mild physical stimulus 
       5.  Responding to moderate and severe physical stimulus 
       6.  Not arousable 
S.No GROUP 0  
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r
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H
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s
1 R 80 80 80 78 78 76 76 76 76 78 78 78
2 R 80 80 80 80 80 80 80 80 80 80 80 80
3 R 70 70 70 70 70 70 70 70 70 70 70 70
4 R 80 80 80 78 76 74 74 74 74 70 70 70
5 R 80 80 80 80 80 80 80 80 80 70 70 70
6 R 80 80 80 80 80 78 78 78 78 70 70 70
7 R 80 80 80 80 80 80 80 80 80 74 74 74
8 R 80 80 80 76 76 74 74 72 72 70 70 70
9 R 70 70 70 70 70 70 70 70 70 70 70 70
10 R 70 70 70 70 70 70 70 70 70 70 70 70
11 R 60 60 60 60 60 60 60 60 60 70 74 70
12 R 70 70 70 70 70 70 70 70 70 68 70 68
13 R 80 80 80 78 78 78 76 76 76 64 64 64
14 R 70 70 70 70 70 70 70 70 70 78 78 78
15 R 80 80 80 80 78 78 76 76 76 64 64 64
16 R 80 80 80 80 80 80 80 78 78 78 78 78
17 R 80 80 80 80 80 80 80 78 78 76 76 76
18 R 90 90 90 86 84 80 80 80 80 80 80 80
19 R 70 70 70 70 70 70 70 70 70 70 70 70
20 R 70 70 70 70 70 70 70 70 70 74 74 74
21 R 70 70 70 70 70 70 70 70 70 80 80 80
22 R 70 70 70 70 70 70 70 70 70 78 78 78
23 R 80 80 80 80 78 76 74 74 74 80 80 80
24 R 70 70 70 70 70 70 70 70 70 72 72 72
25 R 70 70 70 70 70 70 70 70 70 70 70 70
26 R 80 80 80 80 80 74 72 70 70 70 70 70
27 R 80 80 80 80 80 80 78 74 70 60 60 60
28 R 70 70 70 70 70 70 70 70 68 70 70 70
29 R 70 70 70 70 70 68 64 64 64 76 76 76
30 R 80 80 80 80 80 80 78 78 78 70 70 70
31 R 70 70 70 70 70 68 64 64 64 76 76 76
32 R 80 80 80 80 80 80 78 78 78 78 78 78
GROUP R_ROPIVACAINE DIASTOLIC BLOOD PRESSURES  CHART (mmHg)
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1 R 90 94 93 92 90 85 85 84 84 72 98 84
2 R 110 112 110 110 108 107 106 104 98 74 70 98
3 R 78 75 74 74 72 72 72 72 70 99 74 70
4 R 84 84 82 80 78 77 76 74 74 98 98 74
5 R 120 116 108 106 104 101 100 99 98 76 97 98
6 R 114 108 104 104 102 100 98 98 97 64 76 97
7 R 82 78 76 77 77 77 77 76 76 74 64 76
8 R 72 66 64 64 64 64 65 64 64 70 72 64
9 R 84 80 78 76 76 76 75 74 72 65 70 72
10 R 77 74 72 72 72 72 70 70 70 78 64 70
11 R 73 68 66 66 66 66 66 65 64 70 66 64
12 R 88 84 82 82 80 80 80 78 76 70 80 76
13 R 78 72 72 71 70 70 72 70 70 72 70 70
14 R 79 74 73 73 72 72 70 70 68 76 72 68
15 R 77 75 74 74 74 74 74 72 70 82 74 70
16 R 81 80 78 77 77 77 76 76 74 72 77 74
17 R 86 87 85 84 84 84 82 82 80 66 84 80
18 R 78 80 78 75 74 74 72 72 70 66 74 70
19 R 72 70 68 65 65 64 64 66 64 73 64 64
20 R 74 77 72 70 70 70 68 66 65 75 70 65
21 R 76 74 75 76 75 75 75 73 71 67 75 71
22 R 77 76 75 75 76 76 75 75 71 75 76 71
23 R 71 70 70 69 68 69 66 67 65 70 69 65
24 R 79 77 77 78 76 76 75 75 73 89 76 73
25 R 69 71 71 70 70 69 71 70 68 87 69 68
26 R 93 93 91 91 91 89 89 89 84 89 89 84
27 R 89 88 88 88 88 87 87 87 83 67 87 83
28 R 92 92 92 90 90 90 90 89 84 96 90 84
29 R 70 69 70 70 70 69 68 67 65 67 68 65
30 R 99 99 98 98 97 96 96 96 90 96 96 90
31 R 70 69 70 70 70 69 68 67 65 88 68 65
32 R 99 99 98 98 97 96 96 96 90 76 96 90
                                               GROUP-R .ROPIVACAINE PULSE RATE CHART (beats/mins)
                                         GROUP R- ROPIVACAINE SYSTOLIC BLOOD PRESSURE  CHART(mmHg)
S.No GROUP 0
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1 R 140 140 140 140 140 140 140 118 140 120 118 118
2 R 130 130 130 130 130 130 130 126 130 126 126 126
3 R 120 120 120 120 120 120 120 118 120 118 118 118
4 R 120 120 120 120 120 116 116 110 116 110 110 110
5 R 130 130 130 130 130 128 128 128 128 128 128 128
6 R 140 140 140 140 140 136 136 120 136 120 120 120
7 R 120 120 120 120 120 120 118 128 118 128 128 128
8 R 130 130 130 130 130 128 128 120 128 120 120 120
9 R 120 120 120 120 120 120 118 110 118 110 110 110
10 R 110 120 118 118 110 110 110 118 110 118 118 118
11 R 110 110 110 110 110 110 110 136 110 136 136 136
12 R 120 120 120 120 120 120 118 118 118 118 118 118
13 R 130 130 130 130 130 130 128 110 126 110 110 110
14 R 110 120 120 120 110 110 110 128 110 128 128 126
15 R 110 120 118 118 116 110 110 110 110 110 110 110
16 R 130 130 130 130 130 128 128 128 128 128 128 126
17 R 120 120 120 120 120 120 120 118 118 140 118 140
18 R 130 130 130 128 128 126 126 126 126 130 126 130
19 R 120 130 130 130 120 120 118 118 118 120 118 120
20 R 110 110 110 110 110 110 110 110 110 116 110 116
21 R 130 130 130 130 130 128 128 128 128 128 128 128
22 R 120 120 120 120 120 120 120 120 120 136 120 136
23 R 130 130 130 130 130 130 128 128 128 118 128 118
24 R 120 120 120 120 120 120 120 120 120 128 120 128
25 R 110 110 110 110 110 110 110 110 110 118 110 118
26 R 120 120 120 120 120 120 118 118 118 110 118 110
27 R 140 140 140 140 140 136 136 136 136 110 136 110
28 R 120 120 120 120 120 120 118 118 118 118 118 118
29 R 110 110 110 110 110 110 110 110 110 128 110 126
30 R 130 130 130 130 130 128 128 128 126 110 128 110
31 R 110 110 110 110 110 110 110 110 110 110 110 110
32 R 130 130 130 130 130 128 128 128 126 128 128 128
S.No GROUP 0
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1 R 100 100 100 100 100 100 100 100 99 100 100 99
2 R 100 100 100 100 100 99 99 100 99 100 99 99
3 R 100 100 100 100 100 100 99 99 99 100 99 100
4 R 100 100 100 100 100 100 100 99 100 100 100 99
5 R 100 100 99 98 98 98 98 100 98 98 98 99
6 R 99 99 99 99 99 99 99 98 99 99 99 100
7 R 100 100 100 99 99 99 99 99 99 99 99 98
8 R 99 99 99 99 99 99 99 99 99 99 99 99
9 R 100 100 100 99 99 99 99 99 99 99 99 99
10 R 100 100 100 100 100 99 99 99 99 100 99 99
11 R 100 100 100 99 99 99 99 99 99 99 99 99
12 R 100 100 100 99 99 99 99 99 99 99 99 99
13 R 100 100 100 99 99 99 99 99 99 99 99 99
14 R 100 100 100 100 100 99 99 99 99 100 99 99
15 R 100 100 100 99 99 99 99 99 99 99 99 99
16 R 100 100 100 99 99 99 99 99 99 99 99 99
17 R 100 100 100 100 99 99 99 99 99 99 99 99
18 R 99 99 99 99 99 98 98 99 99 99 99 99
19 R 100 100 100 99 99 99 99 99 99 99 99 100
20 R 100 100 100 99 99 99 98 100 98 99 98 99
21 R 100 100 100 99 99 99 98 98 98 99 98 99
22 R 99 99 99 99 98 98 98 99 99 98 99 100
23 R 98 98 98 99 99 99 99 99 99 99 99 98
24 R 100 100 100 100 100 100 99 99 99 100 99 99
25 R 100 100 100 100 100 100 100 99 100 100 100 99
26 R 100 100 100 100 100 100 99 99 99 100 99 99
27 R 99 99 99 99 99 99 99 99 100 99 100 99
28 R 100 100 100 100 100 100 100 99 100 100 100 99
29 R 100 100 100 100 100 100 100 99 100 100 100 99
30 R 99 99 99 99 99 100 100 99 100 99 100 99
31 R 100 100 100 100 100 100 100 99 100 100 100 99
32 R 99 99 99 99 99 100 100 99 100 99 100 99
GROUP R ROPIVACAINE SPO2 CHART
s.no
NAME AGE/SEX IP.NO WT(KG) ASA STATUS DIAGNOSIS & PROCEDURE
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1 RAJKUMAR 19/M 38158 43 I CLOSED LEFT FOREARM #--ORIF WITH PLATING 5 10 11 9 13.5 1.5 2 nil 
2 VINOD 24/M 40961 44 I MONTEAGGI # RIGHT ULNA--ORIF 4 9 12 9 14.5 2 3 nil 
3 KASINADHAN 56/M 42852 49 I LEFT GALEAZZI # --ORIF WITH PLATING 5 9 11 10 14 2 2 nil 
4 AMUDHA 38/F 43415 48 I LEFT ULNA # --ORIF 5 10 12 10 14.5 1 3 nil 
5 RAJESHWARI 43/F 43310 47 I NONUNION LEFT BB #--ORIF WITH PLATING WITH BONE GRAFT 4 8 12 9 14.5 1 2 nil 
6 MAHENDIRAN 21/M 46944 39 I RIGHT ELBOW ORTHRODESIS--ELBOW ORTHROLYSIS 4 8 11 9 14 1.5 2 nil 
7 MANIKANDAN 36/M 42843 45 I # RIGHT ULNA --ORIF WITH PLATING 4 8 10 9 13 2 2 nil 
8 MURALI 30/M 46442 46 I LEFT BARTON #--ORIF WITH PLATING 4 9 11 9 13.5 2 3 nil 
9 VINOTH 28/M 40038 44 I THROUGH ELBOW AMPUTATION-REVISION AE AMPUTATION 4 8 12 10 15 2 2 nil 
10 SURESHKUMAR 28/M 48797 43 I INFECTED IMPLANT LEFT ULNA-IMPLANT EXIT 5 8 12 11 15 2 2 nil 
11 RAJENDIRAN 47/M 47221 54 II INFECTED IMPLANT right ULNA-IMPLANT EXIT 4 9 11 9 14 3 3 nil 
12 JAYARANI 42/F 43543 52 II
CLOSED RIGHT BB# FOREARM-ORIF WITH PLATING WITH 
BONE GRAFTING 4 7 11 10 14 1.5 2 nil 
13 BOOMADEVI 28/F 48860 48 I CLOSED RIGHT LOWER RADIUS #-ORIF WITH PLATING 5 8 10 9 13 2.5 2 nil 
14 SURYA 19/M 51703 39 I CLOSED # BB LEFT FOREARM -ORIF WITH K WIRE FIXATION 5 7 11 9 14 1.5 2 nil 
15 VIGNESH 19/M 50014 40 I CLOSED DISLOCATON LEFT ELBOW # -ORIF 5 9 12 10 15 2.5 2 nil 
16 MARIMUTHU 40/M 41946 52 I LEFT ULNA # --ORIF 4 8 12 10 15 2 2 nil 
17 SUDHAKAR 36/M 52923 48 I
CLOSED DISLOCATION RIGHT ELBOW # WITH RIGHT RADIUS 
HEAD # -ORIF WITH K WIRE 4 9 11 9 14 2 3 nil 
18 MANIKANDAN 26/M 52602 49 I CLOSED # BB RIGHT FOREARM-ORIF WITH PLATING 5 8 11 9 14 2 3 nil 
19 MATHIYALAGAN 43/M 49467 50 I CLOSED DISLOCATION LEFT ELBOW # -ORIF 4 7 12 10 14 1.5 3 nil 
20 SUDHA 36/F 52923 47 I CLOSED DISLOCATION RIGHT ELBOW# -ORIF 4 8 10 9 13 1.5 3 nil 
21 DHANAPAL 59/M 31500 58 II # BB LEFT FOREARM--ORIF WITH PLATING 5 9 12 9 14.5 1 3 nil 
22 SUNDARI 36/F 52925 51 I
CLOSED RIGHT DISLOCATION RIGHT ELBOW WITH RADIAL 
HEAD #--ORIF WITH PLATING 4 9 11 10 13 1 2 nil 
23 SIVAPRAKASAM 23/F 98289 35 I CLOSED # LEFT FOREARM --ORIF 5 9 12 9 13.5 1.5 2 nil 
24 MARAGATHAMANI 56/F 89540 58 II CLOSED # RIGHT FOREARM --ORIF 5 9 11 9 14 2 2 nil 
25 SIVA 52/M 49907 55 I CLOSED #BB FOREARM LEFT--ORIF WITH PLATING 4 9 12 9 14.5 2 2 nil 
26 DHANASEKARAN 19/M 54790 44 I CLOSED # LOWER RADIUS &ULNA--ORIF WITH K WIRE FIXATION 4 8 12 10 14.5 1.5 3 nil 
27 GOPALSAMY 28/M 52979 49 I CLOSED LEFT FOREARM #--ORIF WITH PLATING 5 9 11 9 14 1.5 2 nil 
28 DHANAPAL 59/M 54097 57 I RIGHT ULNA # -ORIF 4 8 11 9 14 1.5 2 nil 
29 SELVI 22/F 58357 46 I CLOSED RIGHT BB# --ORIF WITH PLATING 4 9 12 10 15 1.5 3 nil 
30 DIVYADARSHINI 19/F 59555 39 I CLOSED # BB LEFT FOREARM -ORIF WITH K WIRE FIXATION 5 8 11 9 14 2.5 2 nil 
31 LOGANATHAN 22/M 57803 46 I GRADE I BB # LEFT FOREARM-ORIF ADCD 4 8 12 9 14 1.5 2 nil 
32 SIVAGYANAM 50/F 59824 49 I LEFT GALEZZI # -ORIF WITH PLATING 5 9 12 9 15 1.5 3 nil 
          GROUP RC
S.No GROUP 0
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1 RC 80 80 80 78 78 76 76 76 76 70 76 78
2 RC 80 80 78 78 76 76 74 74 72 74 74 74
3 RC 70 70 70 70 68 64 64 64 64 74 64 76
4 RC 78 78 78 78 76 70 70 70 70 68 70 66
5 RC 80 80 80 80 76 76 74 74 74 68 74 76
6 RC 80 80 80 80 80 76 76 74 74 76 76 76
7 RC 70 70 70 70 70 70 68 68 68 76 68 68
8 RC 70 70 70 70 68 68 68 68 66 70 68 64
9 RC 80 80 80 80 78 78 76 76 74 76 76 74
10 RC 80 80 80 80 78 78 76 76 76 74 76 64
11 RC 70 70 70 70 70 70 70 70 70 66 70 70
12 RC 80 80 80 80 78 78 78 76 74 66 78 66
13 RC 80 80 80 80 78 76 76 74 74 66 74 76
14 RC 70 70 70 70 68 66 66 66 66 78 74 76
15 RC 70 70 70 70 68 68 68 66 64 76 66 76
16 RC 70 70 70 70 68 68 66 66 64 64 64 76
17 RC 80 80 80 80 78 78 78 78 78 64 76 76
18 RC 80 80 80 80 78 78 76 76 74 78 74 72
19 RC 80 80 80 80 80 78 78 76 76 74 64 64
20 RC 70 70 70 70 68 68 68 66 66 76 70 70
21 RC 80 80 80 80 80 78 78 76 76 66 74 74
22 RC 80 80 80 80 80 78 76 76 76 76 74 74
23 RC 70 70 70 70 68 68 68 68 68 76 68 68
24 RC 70 70 70 70 68 68 66 64 64 68 68 66
25 RC 80 80 80 80 78 78 76 74 74 64 76 74
26 RC 70 70 70 70 68 68 66 66 64 74 76 76
27 RC 70 70 70 70 70 70 70 70 70 76 70 70
28 RC 70 70 70 70 68 68 68 66 66 76 76 74
29 RC 80 80 80 78 78 78 76 76 76 66 74 74
30 RC 80 80 80 78 78 76 76 76 76 76 66 66
31 RC 80 80 80 78 78 78 76 76 76 76 66 64
32 RC 80 80 80 78 78 76 76 76 76 68 66 64
GROUP RC ROPIVACAINE AND CLONIDINE DIASTOLIC BLOOD PRESSURES  CHART (mmHg)
S.No GROUP 0
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1 RC 130 130 128 126 122 126 130 130 132 140 140 140
2 RC 120 120 118 116 116 120 122 124 126 130 130 130
3 RC 120 120 118 116 120 120 120 120 122 120 124 124
4 RC 126 126 126 126 126 126 130 130 132 128 126 126
5 RC 130 130 130 128 130 130 130 132 132 140 140 140
6 RC 140 140 140 138 140 140 140 140 140 116 122 122
7 RC 110 110 110 110 110 106 110 114 116 118 120 120
8 RC 120 120 120 118 120 120 120 122 122 108 110 112
9 RC 110 110 110 110 110 110 110 112 114 124 126 128
10 RC 130 130 130 128 130 130 130 128 128 116 120 120
11 RC 120 120 120 118 120 118 122 126 126 116 116 116
12 RC 130 130 130 128 130 128 130 132 132 116 120 120
13 RC 120 120 120 118 118 120 120 124 124 134 140 140
14 RC 130 130 130 128 128 130 130 132 132 116 120 120
15 RC 120 120 120 118 118 120 120 124 126 134 140 140
16 RC 110 110 110 110 110 110 114 122 124 116 120 120
17 RC 140 140 140 138 138 140 140 140 140 130 130 132
18 RC 130 130 130 130 128 130 130 130 130 122 124 126
19 RC 120 120 120 120 122 120 120 124 124 120 120 122
20 RC 130 130 130 128 128 128 128 126 126 130 130 132
21 RC 140 140 140 138 138 140 140 140 140 130 132 132
22 RC 120 120 120 120 120 116 116 122 122 140 140 140
23 RC 120 120 120 118 118 116 118 120 120 110 114 116
24 RC 110 110 110 108 108 106 108 110 112 120 122 122
25 RC 130 130 130 128 128 124 124 126 128 110 112 114
26 RC 120 120 120 118 118 116 116 120 120 130 128 128
27 RC 120 120 120 120 120 118 116 116 116 122 126 126
28 RC 120 120 120 118 118 116 116 120 120 130 132 132
29 RC 140 140 138 138 136 136 134 140 140 120 124 124
30 RC 120 120 120 118 118 114 116 120 120 130 132 132
31 RC 140 140 138 138 136 136 134 140 140 120 124 126
32 RC 120 120 120 118 118 114 116 120 120 114 122 124
                        GROUP RC_ROPIVACAINE  AND CLONIDINE  SBP CHART (mmHg)
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1  RC 100 100 99 100 100 100 100 100 100 100 98 99
2 RC 99 99 99 100 100 100 100 99 99 100 99 98
3 RC 100 100 100 100 100 100 100 100 100 100 99 99
4 RC 100 100 100 99 99 100 100 98 99 99 98 99
5 RC 100 100 100 100 100 98 99 99 99 99 99 99
6 RC 99 99 99 100 100 99 99 99 99 99 98 99
7 RC 100 100 100 100 100 99 99 99 99 99 99 99
8 RC 100 100 100 100 99 99 99 99 99 98 98 98
9 RC 100 100 100 100 99 98 98 98 98 98 98 99
10 RC 99 99 99 99 98 98 98 98 99 98 99 99
11 RC 100 100 100 100 99 99 98 98 99 99 98 99
12 RC 100 100 100 99 99 99 99 99 99 98 98 98
13 RC 100 100 100 100 98 98 98 99 99 99 99 99
14 RC 100 100 100 100 99 99 99 98 99 99 98 99
15 RC 99 99 100 99 99 99 99 99 99 98 99 99
16 RC 100 100 100 100 99 98 98 99 99 98 98 99
17 RC 99 99 99 99 98 98 98 98 99 99 100 100
18 RC 100 100 100 100 99 99 99 99 98 98 99 99
19 RC 98 98 98 98 99 99 99 99 99 99 100 100
20 RC 100 100 100 99 99 99 99 98 99 98 98 99
21 RC 99 99 99 99 99 99 99 99 99 99 99 99
22 RC 100 100 100 100 99 99 99 98 99 98 99 99
23 RC 100 100 100 100 99 99 99 99 99 98 99 99
24 RC 100 100 100 99 99 99 99 98 98 99 99 99
25 RC 100 100 100 99 99 99 99 98 99 98 98 98
26 RC 99 99 99 98 98 99 99 99 99 98 98 99
27 RC 100 100 100 99 99 98 98 98 99 99 98 99
28 RC 100 100 100 99 99 98 98 98 98 98 99 99
29 RC 99 99 99 98 98 98 98 99 99 99 99 99
30 RC 100 100 100 99 99 99 99 98 99 98 98 99
31 RC 99 99 99 98 98 98 98 99 99 99 99 99
32 RC 100 100 100 99 99 99 99 98 99 99 99 99
GROUP RC ROPIVACAINE AND CLONIDINE SPO2 CHART
